Methods and compositions for treating ophthalmic diseases
Patent Information
- Application Number
- JP2023532375
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-12-02
- Filing Date
- 2021-12-02
- Publication Date
- 2024-12-03
- Estimated Expiration
- Not applicable · inactive patent
Abstract
Description
Technical Field
[0001]
[0001] Methods and compositions for treating ophthalmic diseases including dry eye syndrome and uveitis using Bruton's tyrosine kinase (BTK) inhibitors are disclosed herein.
Background Art
[0002]
Element 0002
[0003]
Element 0003
[0004] Bruton's tyrosine kinase (BTK) is a Tec-family non-receptor protein kinase expressed in B cells and myeloid cells. Functional mutations in human BTK result in a primary immunodeficiency disorder called XLA, characterized by impaired B cell development with disruption between the pro-B cell and pre-B cell phases. This results in an almost complete absence of human B lymphocytes and a marked decrease in all classes of serum immunoglobulins.
[0005]
[0005] This disclosure relates to a method for treating ophthalmic diseases in humans using a BTK inhibitor. [Overview of the project]
[0006]
[0006] In one embodiment, the present disclosure relates to a method for treating an ophthalmic disease in a human subject that requires the administration of a Bruton's tyrosine kinase (BTK) inhibitor compound to a human subject in an amount effective to treat the ophthalmic disease in the human subject.
[0007]
[0007] In one embodiment, the present disclosure relates to a method for reducing the immune response in a human subject with an ophthalmic disease, comprising the step of administering to the human subject an amount of a Bruton's tyrosine kinase (BTK) inhibitor compound effective in reducing the immune response in the human subject.
[0008]
[0008] In the embodiment, the BTK inhibitor compound is 1-(4-(((6-amino-5-(4-phenoxyphenyl)pyrimidine-4-yl)amino)methyl)-4-fluoropiperidine-1-yl)propa-2-en-1-one or a pharmaceutically acceptable salt thereof.
[0009]
[0009] In the embodiment, the step of administering a BTK inhibitor compound reduces inflammation in the eye of a human subject.
[0010]
[0010] In this embodiment, the ophthalmic disease is inflammation of the eye.
[0011]
[0011] In this embodiment, the ophthalmic disease is selected from dry eye disease, uveitis, postoperative eye inflammation, corneal transplant, ocular graft-versus-host disease (GVHD), allergy, allergic conjunctivitis, non-allergic conjunctivitis, or infectious conjunctivitis.
[0012]
[0012] In this embodiment, the ophthalmic disease is dry eye disease.
[0013]
[0013] In this embodiment, the ophthalmic disease is a tear-deficient type of dry eye disease.
[0014]
[0014] In this embodiment, the ophthalmic disease is an evaporative dry eye disease.
[0015]
[0015] In this embodiment, the ophthalmic disease is a mixed type of dry eye disease characterized by tear reduction and evaporation.
[0016]
[0016] In this embodiment, the ophthalmic disease is uveitis.
[0017]
[0017] In this embodiment, the ophthalmic disease is infectious uveitis.
[0018]
[0018] In this embodiment, the ophthalmic disease is non-infectious uveitis.
[0019]
[0019] In this embodiment, the ophthalmic disease is anterior uveitis.
[0020]
[0020] In another embodiment, the ophthalmic disease is intermediate uveitis.
[0021]
[0021] In this embodiment, the ophthalmic disease is posterior uveitis.
[0022]
[0022] In this embodiment, the ophthalmic disease is panuveitis.
[0023]
[0023] In the embodiment, the administration step includes local administration to the eye of a human subject.
[0024]
[0024] In an embodiment, the administering step includes an intravitreal injection into the eye of a human subject.
[0025]
[0025] In an embodiment, the administering step includes an intravitreal injection into the eye of a human subject.
[0026]
[0026] In an embodiment, the administering step includes a periocular administration to a human subject.
[0027]
[0027] In an embodiment, the administering step includes an oral administration to a human subject.
[0028]
[0028] In an embodiment, the administering step includes an intravenous injection (including intravenous infusion) to a human subject.
[0029]
[0029] In an embodiment, the compound is administered as nanoparticles comprising the compound.
[0030]
[0030] In an embodiment, the compound is in a dosage form selected from a solution, suspension, emulsion, microemulsion, ointment, gel, hydrogel, drug delivery device, tablet, or capsule.
[0031]
[0031] In an embodiment, the drug delivery device is an intravitreal insert for sustained release of a BTK inhibitor compound.
[0032]
[0032] In an embodiment, the dosage form is a sustained release form, long-term release form, controlled release form, or a combination thereof.
[0033]
[0033] In an embodiment, the sustained release, long-term release, or controlled release dosage form comprises a pegylated BTK inhibitor.
[0034]
[0034] In an embodiment, the compound is administered as particles that self-aggregate upon administration to form a depot.
[0035]
[0035] In an embodiment, the particles further comprise a polymer.
[0036]
[0036] In the embodiment, the polymer is selected from the group consisting of chitosan, gelatin, sodium alginate, albumin, poly-L-lactide (PLLA), poly(lactic acid) (PLA), poly(glycolic acid) (PGA), polylactic acid glycolic acid copolymer (PLGA), polycaprolactone, polylactic acid caprolactone copolymer, poly(methyl methacrylates), poloxamer, poly(ethylene glycol) (PEG), PEG-PLLA, PEG-PLGA, poly(methyl vinyl ether / maleic anhydride), cellulose acetate phthalate, and combinations thereof.
[0037]
[0037] In the embodiment, the polymer is polylactic acid glycolic acid copolymer (PLGA), PEG-PLGA, or a combination thereof.
[0038]
[0038] In this embodiment, human eye T cells overexpress lymphocyte function-associated antigen (LFA-1).
[0039]
[0039] In this embodiment, the step of administering the compound reduces the expression of LFA-1.
[0040]
[0040] In this embodiment, the compound inhibits intercellular adhesion molecule 1 (ICAM-1) of the eye of a human subject.
[0041]
[0041] In this embodiment, ICAM-1 is present on antigen-presenting cells (APCs) of the eye of a human subject.
[0042]
[0042] In this embodiment, ICAM-1 is present on vascular endothelial cells of the eye of a human subject.
[0043]
[0043] In this embodiment, ICAM-1 is present on the corneal epithelial cells of a human eye.
[0044]
[0044] In the embodiment, the step of administering the compound reduces the level of inflammatory cytokines.
[0045]
[0045] In the embodiment, the inflammatory cytokine is selected from IL-1β, IL-6, INF-γ, TNF-α, or a combination thereof.
[0046]
[0046] In the embodiment, the step of administering the compound reduces APCs on the ocular surface, the maturation of APCs, or both.
[0047]
[0047] In the embodiment, the APC is a monocyte, macrophage, dendritic cell, B cell, or a combination thereof.
[0048]
[0048] In this embodiment, the human subject has markers for ophthalmic diseases.
[0049]
[0049] In the embodiment, the markers are elevated inflammatory cytokines, elevated chemokines, elevated matrix metalloproteinases (MMPs), elevated Toll-like receptor 2 (TLR2), elevated nuclear factor κB (NF-κB), elevated tumor necrosis factor α (TNF-α), or a combination thereof.
[0050]
[0050] In the embodiment, the inflammatory cytokine is selected from IL-1β, IL-6, INF-γ, TNF-α, or a combination thereof.
[0051]
[0051] In this embodiment, the human subject has an autoimmune disease or an inflammatory disease in addition to an ophthalmic disease.
[0052]
[0052] In this embodiment, the autoimmune disease or inflammatory disease is rheumatoid arthritis, Sjögren's syndrome, Vogt-Koyanagi-Harada (VKH) disease, juvenile idiopathic arthritis, Behçet's disease, systemic sarcoidosis, spondyloarthropathy (such as HLA-B27-related spondyloarthropathy), Blau syndrome, or IgG-4-related disease (IgG4-RD).
[0053]
[0053] In the embodiment, the administration step is performed at a frequency of three times a day, twice a day, once a day, every other day, three times a week, twice a week, every week, every two weeks, twice a month, every month, every two months, or every three months.
[0054]
[0054] In this embodiment, the immune response is an innate immune response, an adaptive immune response, or both. [Modes for carrying out the invention]
[0055]
[0055] Preferred embodiments of the Disclosure are shown and described herein, but such embodiments are provided for illustrative purposes only and are not intended to otherwise limit the scope of the Disclosure. Various alternatives to the embodiments described may be adopted in the practice of the Disclosure.
[0056]
[0056] Unless otherwise defined, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art to which this disclosure belongs.
[0057]
[0057] The terms “effective amount for ~,” “effective amount,” or “therapeutic effective amount” refer to the amount of the medicinal active ingredient or combination of medicinal active ingredients described herein that is sufficient to achieve the intended application, including but not limited to the treatment of a disease. The therapeutic effective amount may vary depending on the intended application (in vitro or in vivo), or the subject and condition being treated (e.g., the subject’s weight, age, and sex), the severity of the condition, the method of administration, and other factors that can be readily determined by those skilled in the art. The term also applies to doses that induce a specific response in target cells (e.g., reduced platelet adhesion and / or cell migration). The specific dose will vary depending on the particular compound selected, the administration plan to be followed, whether the compound is administered in combination with other compounds, the timing of administration, the tissue to which it is administered, and the physical delivery system through which the compound is carried.
[0058]
[0058] “Therapeutic effect” means, as used herein, the therapeutic and / or preventive benefits described above. A preventive effect includes delaying or eliminating the onset of a disease or condition, delaying or eliminating the onset of symptoms of a disease or condition, slowing, stopping, or reversing the progression of a disease or condition, or any combination thereof.
[0059]
[0059] The terms "QD", "qd", or "qd" mean once a day, once a day, or once daily. "BID", "bid", or "bid" mean twice a day, twice a day, or twice daily. "TID", "tid", or "tid" mean three times a day, three times a day, or three times daily. "QID", "qid", or "qid" mean four times a day, four times a day, or four times daily.
[0060]
[0060] The term "Multivariance Index (PDI)" is given by the formula: PDI = (σ / 2a) 2 As shown, PDI is defined as the square of the ratio of the standard deviation (σ) of the particle size distribution to the mean particle size (2a). PDI is used to estimate the degree of non-uniformity in the size distribution of nanoparticles; a larger PDI value corresponds to a larger size distribution in the particle sample. PDI can also indicate particle aggregation, along with the consistency and efficiency of particle surface modification. When the PDI value is less than 0.1, the sample is considered monodisperse.
[0061]
[0061] The term "pharmaceutically acceptable salt" refers to salts obtained from various organic and inorganic counterions known in the art. Pharmaceutically acceptable acid addition salts can be formed using inorganic and organic acids. Inorganic acids from which salts can be obtained include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, and phosphoric acid. Organic acids from which salts can be obtained include, for example, acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, and salicylic acid. Pharmaceutically acceptable base additions can be formed using inorganic and organic bases. Inorganic bases from which salts can be obtained include, for example, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, and aluminum. Organic bases from which salts can be obtained include, for example, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins. Specific examples include isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine. In selected embodiments, pharmaceutically acceptable base addition salts are selected from ammonium salts, potassium salts, sodium salts, calcium salts, and magnesium salts.
[0062]
[0062] “Pharmacochemically acceptable carrier” or “Pharmacochemically acceptable excipient” is intended to include all solvents, dispersions, coatings, antimicrobial and antifungal agents, isotonic agents, and absorption retarders. The use of such media and agents for pharmacochemical active ingredients is well known in the art. Unless any conventional media or agent is incompatible with the pharmacochemical active ingredient, its use in the therapeutic compositions of the present disclosure is intended. Supplementary active ingredients may also be incorporated into the compositions described.
[0063]
[0063] A "solvate" refers to a compound that is physically associated with one or more molecules of a pharmaceutically acceptable solvent.
[0064]
[0064] The compounds of the present disclosure also include the crystalline and amorphous forms of the compounds listed in Table 1, including, for example, polymorphs, pseudopolymorphs, solvates, hydrates, unsolvated polymorphs (including anhydrous), conformational polymorphs, and amorphous forms of the compounds, as well as mixtures thereof.
[0065]
[0065] For example, when a range is used herein to describe a physical or chemical property such as molecular weight or chemical formula, it is intended to include all combinations and subcombinations of the range and specific embodiments therein. The use of the term “about” when referring to a numerical value or numerical range means that the numerical value or numerical range referred to is an approximation within the range of experimental variation (or within the statistical error of experiment), and therefore the numerical value or numerical range may vary, for example, from 1% to 15% of the stated numerical value or numerical range. The term “comprising” (and related terms such as “comprise” or “comprises” or “has” or “including”) includes embodiments such as any composition, method, or process embodiment that “consists of” or “essentially consists of” the described properties.
[0066] A method for treating ophthalmic diseases and inflammation using BTK inhibitors.
[0066] This disclosure relates to a method for treating ophthalmic diseases, comprising the step of administering a Bruton's tyrosine kinase (BTK) inhibitor compound to a person in need thereof. Ophthalmic diseases include inflammation of the eye, dry eye diseases (including depressive dry eye disease, evaporative dry eye disease, and mixed depressive and evaporative dry eye disease), uveitis (including infectious uveitis, non-infectious uveitis, anterior uveitis, intermediate uveitis, posterior uveitis, and panuveitis), postoperative inflammation of the eye, corneal transplantation, ocular graft-versus-host disease (GVHD), allergies, allergic conjunctivitis, non-allergic conjunctivitis, and infectious conjunctivitis. The BTK inhibitor compound is administered in an amount effective to treat the ophthalmic disease of a person.
[0067]
[0067] The disclosure also relates to a method for reducing inflammation of the human eye in need, comprising the step of administering a BTK inhibitor compound to a human. The BTK inhibitor compound is administered in an amount effective to reduce inflammation of the human eye.
[0068]
[0068] The disclosure further relates to a method for reducing the immune response in a person having an ophthalmic disease and requiring such reduction, comprising the step of administering a BTK inhibitor compound to a person. The immune response includes innate immune responses, adaptive immune responses, or both. Ophthalmic diseases include inflammation of the eye, dry eye diseases (including depressive dry eye diseases, evaporative dry eye diseases, and mixed depressive and evaporative dry eye diseases), uveitis (including infectious uveitis, non-infectious uveitis, anterior uveitis, intermediate uveitis, posterior uveitis, and panuveitis), postoperative inflammation of the eye, corneal transplantation, ocular graft-versus-host disease (GVHD), allergies, allergic conjunctivitis, non-allergic conjunctivitis, and infectious conjunctivitis. The BTK inhibitor compound is administered in an amount effective to reduce the immune response in a person having an ophthalmic disease.
[0069]
[0069] The disclosure also relates to a method for treating an ophthalmic disease, comprising the step of administering a pharmaceutical composition comprising a BTK inhibitor compound to a person in need thereof. The ophthalmic diseases include inflammation of the eye, dry eye diseases (including depressive dry eye disease, evaporative dry eye disease, and mixed depressive and evaporative dry eye disease), uveitis (including infectious uveitis, non-infectious uveitis, anterior uveitis, intermediate uveitis, posterior uveitis, and panuveitis), postoperative inflammation of the eye, corneal transplantation, ocular graft-versus-host disease (GVHD), allergies, allergic conjunctivitis, non-allergic conjunctivitis, and infectious conjunctivitis. The pharmaceutical composition is administered in an amount effective to treat the ophthalmic disease of a person.
[0070]
[0070] The disclosure also relates to a method for reducing eye inflammation in a person requiring it, comprising the step of administering a pharmaceutical composition comprising a BTK inhibitor compound to a person. The pharmaceutical composition is administered in an amount effective to reduce eye inflammation in a person.
[0071]
[0071] The disclosure further relates to a method for reducing the immune response in a person having an ophthalmic disease and requiring such reduction, comprising the step of administering a pharmaceutical composition comprising a BTK inhibitor compound to a person. The immune response includes innate immune responses, adaptive immune responses, or both. Ophthalmic diseases include inflammation of the eye, dry eye diseases (including depressive dry eye diseases, evaporative dry eye diseases, and mixed depressive and evaporative dry eye diseases), uveitis (including infectious uveitis, non-infectious uveitis, anterior uveitis, intermediate uveitis, posterior uveitis, and panuveitis), postoperative inflammation of the eye, corneal transplantation, ocular graft-versus-host disease (GVHD), allergies, allergic conjunctivitis, non-allergic conjunctivitis, and infectious conjunctivitis. The pharmaceutical composition is administered in an amount effective to reduce the immune response in a person having an ophthalmic disease.
[0072]
[0072] This disclosure relates to a method for reducing the expression of lymphocyte function-associated antigen (LFA-1) in the human eye, comprising the step of administering a BTK inhibitor compound (including a pharmaceutical composition comprising a BTK inhibitor compound) to a human. In the embodiments, the human has an ophthalmic disease as described herein. The BTK inhibitor compound is administered in an amount effective to reduce the expression of LFA-1 in the human eye. In the embodiments, T cells in the eye of a human with an ophthalmic disease overexpress LFA-1, and administration of the BTK inhibitor compound reduces the expression of LFA-1 in the human eye.
[0073]
[0073] This disclosure relates to a method for inhibiting intercellular adhesion molecule 1 (ICAM-1) of the human eye, comprising the step of administering a BTK inhibitor compound (including a pharmaceutical composition comprising a BTK inhibitor compound) to a human. In embodiments, the human has an ophthalmic disease as described herein. The BTK inhibitor compound is administered in an amount effective to inhibit ICAM-1 in the human eye. In embodiments, ICAM-1 is present on antigen-presenting cells (APCs) of the human eye, and administration of the BTK inhibitor compound inhibits ICAM-1 on the APCs of the human eye. In embodiments, ICAM-1 is present on vascular endothelial cells of the human eye, and administration of the BTK inhibitor compound inhibits ICAM-1 on the vascular endothelial cells of the human eye. In embodiments, ICAM-1 is present on corneal endothelial cells of the human eye, and administration of the BTK inhibitor compound inhibits ICAM-1 on corneal endothelial cells of the human eye.
[0074]
[0074] This disclosure relates to a method for reducing the level of inflammatory cytokines in a human (including the human eye), comprising the step of administering a BTK inhibitor compound (including a pharmaceutical composition comprising a BTK inhibitor compound) to a human. In embodiments, the human has an ophthalmic disease as described herein. The BTK inhibitor compound is administered in an amount effective to reduce the level of inflammatory cytokines in the human (including the human eye). In embodiments, the inflammatory cytokine is selected from IL-1β, IL-6, INF-γ, TNF-α, or a combination thereof.
[0075]
[0075] This disclosure relates to a method for reducing APCs, APC maturation, or both on the ocular surface of a human eye, comprising the step of administering a BTK inhibitor compound (including a pharmaceutical composition comprising a BTK inhibitor compound) to a human. In embodiments, the human has an ophthalmic disease as described herein. The BTK inhibitor compound is administered in an amount effective to reduce APCs, APC maturation, or both on the ocular surface of the human eye. In embodiments, the APCs are monocytes, macrophages, dendritic cells, B cells, or a combination thereof.
[0076]
[0076] In the embodiment, the human has markers for ophthalmic disease. In the embodiment, the markers are elevated inflammatory cytokines, elevated chemokines, elevated matrix metalloproteinases (MMPs), elevated Toll-like receptor 2 (TLR2), elevated nuclear factor κB (NF-κB), elevated tumor necrosis factor α (TNF-α), or a combination thereof. In the embodiment, the inflammatory cytokines are selected from IL-1β, IL-6, INF-γ, TNF-α, or a combination thereof.
[0077]
[0077] In the embodiment, the human has an autoimmune disease or inflammatory disease in addition to an ophthalmic disease. In the embodiment, the autoimmune disease or inflammatory disease is rheumatoid arthritis, Sjögren's syndrome, Vogt-Koyanagi-Harada (VKH) disease, juvenile idiopathic arthritis, Behçet's disease, systemic sarcoidosis, spondyloarthropathy (such as HLA-B27-associated spondyloarthropathy), Blau syndrome, or IgG-4-associated disease (IgG4-RD).
[0078]
[0078] In the embodiment, the BTK inhibitor compound is selected from the compounds listed in Table 1 or pharmaceutically acceptable salts thereof.
[0079] [Table 1] TIFF2023551679000002.tif195149 TIFF2023551679000003.tif194149 TIFF2023551679000004.tif202149 TIFF2023551679000005.tif187149 TIFF2023551679000006.tif157149 TIFF2023551679000007.tif172149 TIFF2023551679000008.tif179149 TIFF2023551679000009.tif172149 TIFF2023551679000010.tif211149 TIFF2023551679000011.tif172149 TIFF2023551679000012.tif211149 TIFF2023551679000013.tif203149 TIFF2023551679000014.tif157149 TIFF2023551679000015.tif203149 TIFF2023551679000016.tif172149 TIFF2023551679000017.tif195149 TIFF2023551679000018.tif203149 TIFF2023551679000019.tif203149 TIFF2023551679000020.tif164149 TIFF2023551679000021.tif164149 TIFF2023551679000022.tif172149 TIFF2023551679000023.tif187149 TIFF2023551679000024.tif211149 TIFF2023551679000025.tif179149 TIFF2023551679000026.tif172149 TIFF2023551679000027.tif164149 TIFF2023551679000028.tif172149 TIFF2023551679000029.tif195149 TIFF2023551679000030.tif164149 TIFF2023551679000031.tif172149 TIFF2023551679000032.tif211149 TIFF2023551679000033.tif203149 TIFF2023551679000034.tif172149 TIFF2023551679000035.tif164149 TIFF2023551679000036.tif203149 TIFF2023551679000037.tif196149 TIFF2023551679000038.tif211149 TIFF2023551679000039.tif150149 TIFF2023551679000040.tif194149 TIFF2023551679000041.tif155149
[0080]
[0079] In the embodiment, the BTK inhibitor or a pharmaceutically acceptable salt thereof is a reversible BTK inhibitor. In the embodiment, the BTK inhibitor or a pharmaceutically acceptable salt thereof is an irreversible covalent BTK inhibitor.
[0081]
[0080] The disclosure relates to the use of BTK inhibitor compounds for treating human ophthalmic diseases in which such use is required, wherein ophthalmic diseases include inflammation of the eye, dry eye diseases (including depressive dry eye diseases, evaporative dry eye diseases, and mixed depressive and evaporative dry eye diseases), uveitis (including infectious uveitis, non-infectious uveitis, anterior uveitis, intermediate uveitis, posterior uveitis, and panuveitis), postoperative inflammation of the eye, corneal transplantation, ocular graft-versus-host disease (GVHD), allergies, allergic conjunctivitis, non-allergic conjunctivitis, and infectious conjunctivitis. The BTK inhibitor compounds are provided in amounts effective for treating human ophthalmic diseases. In embodiments, the BTK inhibitor compound is one of the compounds listed in Table 1 or a pharmaceutically acceptable salt thereof.
[0082]
[0081] The disclosure further relates to the use of BTK inhibitor compounds to alleviate inflammation of the human eye in which it is needed. The BTK inhibitor compounds are provided in amounts effective for alleviating inflammation of the human eye. In embodiments, the BTK inhibitor compound is one of the compounds listed in Table 1 or a pharmaceutically acceptable salt thereof.
[0083]
[0082] This disclosure further relates to the use of BTK inhibitor compounds to reduce the immune response in a person having an ophthalmic disease and requiring such reduction. The immune response includes innate immune responses, adaptive immune responses, or both. Ophthalmic diseases include inflammation of the eye, dry eye diseases (including depressive dry eye diseases, evaporative dry eye diseases, and mixed depressive and evaporative dry eye diseases), uveitis (including infectious uveitis, non-infectious uveitis, anterior uveitis, intermediate uveitis, posterior uveitis, and panuveitis), postoperative inflammation of the eye, corneal transplantation, ocular graft-versus-host disease (GVHD), allergies, allergic conjunctivitis, non-allergic conjunctivitis, and infectious conjunctivitis. The BTK inhibitor compounds are provided in amounts effective for reducing the immune response in a person having an ophthalmic disease. In embodiments, the BTK inhibitor compounds are the compounds listed in Table 1 or pharmaceutically acceptable salts thereof.
[0084]
[0083] This disclosure relates to the use of the pharmaceutical compositions described herein, comprising BTK inhibitor compounds, for the treatment of human ophthalmic diseases in which such use is required, wherein the ophthalmic diseases include inflammation of the eye, dry eye diseases (including depressive dry eye diseases, evaporative dry eye diseases, and mixed depressive and evaporative dry eye diseases), uveitis (including infectious uveitis, non-infectious uveitis, anterior uveitis, intermediate uveitis, posterior uveitis, and panuveitis), postoperative inflammation of the eye, corneal transplantation, ocular graft-versus-host disease (GVHD), allergies, allergic conjunctivitis, non-allergic conjunctivitis, and infectious conjunctivitis. The pharmaceutical compositions are provided in amounts effective for treating human ophthalmic diseases. In embodiments, the BTK inhibitor compound is one of the compounds listed in Table 1 or a pharmaceutically acceptable salt thereof.
[0085]
[0084] This disclosure further relates to the use of the pharmaceutical compositions described herein, comprising BTK inhibitor compounds for reducing inflammation of the human eye in which it is needed. The pharmaceutical compositions are provided in an amount effective for reducing inflammation of the human eye. In embodiments, the BTK inhibitor compound is one of the compounds listed in Table 1 or a pharmaceutically acceptable salt thereof.
[0086]
[0085] This disclosure further relates to the use of the pharmaceutical compositions described herein, comprising BTK inhibitor compounds for reducing the immune response in a person having an ophthalmic disease and requiring such reduction. The immune response includes innate immune responses, adaptive immune responses, or both. Ophthalmic diseases include inflammation of the eye, dry eye diseases (including depressive dry eye diseases, evaporative dry eye diseases, and mixed depressive and evaporative dry eye diseases), uveitis (including infectious uveitis, non-infectious uveitis, anterior uveitis, intermediate uveitis, posterior uveitis, and panuveitis), postoperative inflammation of the eye, corneal transplantation, ocular graft-versus-host disease (GVHD), allergies, allergic conjunctivitis, non-allergic conjunctivitis, and infectious conjunctivitis. The pharmaceutical compositions are provided in an amount effective to reduce the immune response in a person having an ophthalmic disease. In embodiments, the BTK inhibitor compound is one of the compounds listed in Table 1 or a pharmaceutically acceptable salt thereof.
[0087] Nanoparticle composition
[0086] This disclosure includes pharmaceutical compositions comprising nanoparticles comprising a BTK inhibitor compound. In embodiments, the BTK inhibitor compound is provided in the form of nanoparticles comprising the BTK inhibitor compound. In embodiments, the BTK inhibitor compound is administered as nanoparticles comprising the BTK inhibitor compound. In embodiments, the BTK inhibitor compound is administered as a pharmaceutical composition described herein. In embodiments, the BTK inhibitor compound is administered as a pharmaceutical composition comprising nanoparticles comprising the BTK inhibitor compound. This disclosure includes pharmaceutical compositions comprising nanoparticles comprising a BTK inhibitor, one or more surfactants, and pharmaceutically acceptable excipients. In embodiments, the BTK inhibitor compound is one of the compounds listed in Table 1 or a pharmaceutically acceptable salt thereof. In embodiments, the BTK inhibitor compound is one of the compounds listed in Table 1 or a pharmaceutically acceptable salt thereof.
[0088]
[0087] In the embodiment, the nanoparticles further comprise a polymer. The polymer is selected from the group consisting of chitosan, gelatin, sodium alginate, albumin, poly-L-lactide (PLLA), poly(lactic acid) (PLA), poly(glycolic acid) (PGA), polylactic acid glycolic acid copolymer (PLGA), polycaprolactone, polylactic acid caprolactone copolymer, poly(methyl methacrylates), poloxamer, poly(ethylene glycol) (PEG), PEG-PLLA, PEG-PLGA, poly(methyl vinyl ether / maleic anhydride), cellulose acetate phthalate, and combinations thereof.
[0089]
[0088] In this embodiment, the BTK inhibitor is encapsulated in nanoparticles.
[0090]
[0089] In this embodiment, the polymer is polylactic acid glycolic acid copolymer (PLGA).
[0091]
[0090] In one embodiment, the PLGA has an average molecular weight of about 10 kDa, about 20 kDa, about 30 kDa, about 40 kDa, about 50 kDa, about 60 kDa, about 70 kDa, about 80 kDa, about 90 kDa, about 100 kDa, about 110 kDa, about 120 kDa, about 130 kDa, 140 kDa, or 150 kDa.
[0092]
[0091] In the embodiment, PLGA has a lactic acid / glycolic acid ratio of 5:95, 10:90; 15:85; 20:80, 25:75, 30:70; 35:65, 40:60, 45:55, 50:50, 55:45, 60:40, 65:35, 70:30, 75:25, 80:20, 85:15, 80:19, or 95:5.
[0093]
[0092] In the embodiment, the surfactant is selected from the group consisting of polysorbate, polyvinyl alcohol, methylcellulose, gelatin, albumin, poloxamer, ethylcellulose, crosslinked polyacrylic acid polymer, tocopheryl polyethylene glycol succinate (TPGS), sodium cholate, lipids, stearic acid, and combinations thereof.
[0094]
[0093] In this embodiment, the surfactant is tocopheryl polyethylene glycol succinate (TPGS).
[0095]
[0094] In the embodiment, the nanoparticles further include a stabilizer selected from the group consisting of PVP (povidone), PVA (polyvinyl alcohol), PEG (polyethylene glycol), HPMC (hypromellose), HPC (hydroxypropyl cellulose), HEC (hydroxyethyl cellulose), NaCMC (sodium carboxymethylcellulose), SD (sodium docusate), SLS (sodium lauryl sulfate), PEI (polyethyleneimine), TPGS (D-α-tocopheryl polyethylene glycol succinate), PEO (polyethylene oxide), and PPO (polypropylene oxide).
[0096]
[0095] In this embodiment, the nanoparticles further comprise a hydrogel.
[0097]
[0096] In the embodiment, the hydrogel is selected from the group consisting of poly(propylene oxide), poly(ethylene oxide), poloxamer (pluronic), chitosan, gelatin, cellulose derivatives, glycol chitin, poly(N-isopropylacrylamide) (PNIPAAm), PEG-PLGA-PEG, poly(D,L-lactide)-poly(ethylene glycol)-poly(D,L-lactide) (PDLLA-PEG-PDLLA), and combinations thereof.
[0098] Particle size and morphology
[0097] In some embodiments, the nanoparticles may have a spherical shape. In some embodiments, the nanoparticles may have a cylindrical shape.
[0099]
[0098] In some embodiments, nanoparticles may have a wide variety of non-spherical shapes. Non-spherical nanoparticles may be used to alter uptake by phagocytic cells, thereby altering clearance by the reticuloendothelial system. In some embodiments, non-spherical nanoparticles may be in the shape of a rectangular disc, a high aspect ratio rectangular disc, a rod, a high aspect ratio rod, a worm, a flattened ellipse, an oblong ellipse, an elliptical disc, a UFO, a circular disc, a barrel, a bullet, a pill, a pulley, a biconvex lens shape, a ribbon, a ravioli, a flattened pill, a bicone, a diamond disc, a concave disc, an elongated hexagonal disc, a taco, a wrinkled oblong ellipsoid, a wrinkled flattened ellipsoid, or a porous elliptical disc. Additional shapes other than these are also within the definition of “non-spherical” shape.
[0100]
[0099] In some embodiments, the particles have a median particle size of less than 1000 nm. In some embodiments, the median particle size is in the range of about 1 nm to about 1000 nm. In some embodiments, the median particle size is in the range of about 1 nm to about 500 nm. In some embodiments, the median particle size is in the range of about 1 nm to about 250 nm. In some embodiments, the median particle size is in the range of about 1 nm to about 150 nm. In some embodiments, the median particle size is in the range of about 1 nm to about 100 nm. In some embodiments, the median particle size is in the range of about 1 nm to about 50 nm. In some embodiments, the median particle size is in the range of about 1 nm to about 25 nm. In some embodiments, the median particle size is in the range of about 1 nm to about 10 nm.In some embodiments, the particles are approximately 1 nm, 5 nm, 10 nm, 15 nm, 20 nm, 25 nm, 30 nm, 35 nm, 40 nm, 45 nm, 50 nm, 55 nm, 60 nm, 65 nm, 70 nm, 75 nm, 80 nm, 85 nm, 90 nm, 95 nm, 100 nm, 105 nm, 110 nm, 115 nm, 120 nm, 125 nm, and 130 nm. m, approx. 135nm, approx. 140nm, approx. 145nm, approx. 150nm, approx. 155nm, approx. 160nm, approx. 165nm, approx. 170nm, approx. nm, approximately 200nm, approximately 205nm, approximately 210nm, approximately 215nm, approximately 220nm, approximately 225nm, approximately 230nm, approximately 235nm, approximately 240nm, approximately 245nm, approximately 250nm, approximately 255nm, approximately 260 nm, approximately 265nm, approximately 270nm, approximately 275nm, approximately 280nm, approximately 285nm, approximately 290nm, approximately 295nm, approximately 300nm, approximately 310nm, approximately 320nm, approximately 330nm, approximately 340nm, approximately 35 0nm, about 360nm, about 370nm, about 380nm, about 390nm, about 400nm, about 410nm, about 420nm, about 430nm, about 440nm, about 450nm, about 460nm, about 470nm, about 48 The nanoparticles have a median particle size selected from the group consisting of 0 nm, approximately 490 nm, approximately 500 nm, approximately 525 nm, approximately 550 nm, approximately 575 nm, approximately 600 nm, approximately 625 nm, approximately 650 nm, approximately 675 nm, approximately 700 nm, approximately 725 nm, approximately 750 nm, approximately 775 nm, approximately 800 nm, approximately 825 nm, approximately 850 nm, approximately 875 nm, approximately 900 nm, approximately 925 nm, approximately 950 nm, approximately 975 nm, and approximately 1000 nm. In some embodiments, the nanoparticles have a median particle size of 500 nm. In some embodiments, the nanoparticles have a median particle size of 250 nm.
[0101]
[0100] In some embodiments, the nanoparticles have a median particle size of approximately 5 nm, approximately 10 nm, approximately 15 nm, approximately 20 nm, approximately 25 nm, approximately 30 nm, approximately 35 nm, approximately 40 nm, approximately 45 nm, approximately 50 nm, approximately 55 nm, approximately 65 nm, approximately 70 nm, approximately 75 nm, approximately 80 nm, approximately 85 nm, approximately 90 nm, approximately 95 nm, approximately 100 nm, approximately 105 nm, approximately 110 nm, approximately 115 nm, approximately 120 nm, approximately 125 nm, approximately 130 nm, approximately 135 nm, approximately 140 nm, approximately 145 nm, approximately 150 nm, approximately 155 nm, approximately 160 nm, approximately 165 nm, approximately 170 nm, approximately 175 nm, approximately 180 nm, approximately 185 nm, approximately 190 nm, approximately 195 nm, or approximately 200 nm.
[0102]
[0101] In the embodiment, the nanoparticles have a median particle size of less than approximately 50 nm, less than approximately 60 nm, less than approximately 70 nm, less than approximately 80 nm, less than approximately 90 nm, less than approximately 100 nm, less than approximately 110 nm, less than approximately 120 nm, less than approximately 130 nm, less than approximately 140 nm, less than approximately 150 nm, less than approximately 160 nm, less than approximately 170 nm, less than approximately 180 nm, less than approximately 190 nm, less than approximately 200 nm, less than approximately 210 nm, less than approximately 220 nm, or less than approximately 230 nm.
[0103]
[0102] In this embodiment, the nanoparticles have a median particle size in the range of approximately 5 nm to approximately 200 nm, approximately 10 nm to approximately 190 nm, approximately 15 nm to approximately 180 nm, approximately 20 nm to approximately 175 nm, approximately 25 nm to approximately 170 nm, approximately 30 nm to approximately 165 nm, approximately 35 nm to approximately 160 nm, approximately 40 nm to approximately 155 nm, approximately 45 nm to approximately 150 nm, approximately 50 nm to approximately 145 nm, approximately 55 nm to approximately 140 nm, approximately 60 nm to approximately 135 nm, approximately 65 nm to approximately 130 nm, approximately 70 nm to approximately 125 nm, approximately 75 nm to approximately 120 nm, approximately 80 nm to approximately 115 nm, approximately 85 nm to approximately 110 nm, or approximately 90 nm to approximately 100 nm.
[0104]
[0103] In the embodiment, the nanoparticles have a PDI of about 0.05, about 0.10, about 0.15, about 0.20, about 0.25, about 0.30, about 0.35, about 0.40, about 0.45, about 0.50, about 0.55, about 0.60, about 0.65, about 0.70, about 0.75, about 0.80, about 0.85, about 0.90, about 0.95, or about 1.0.
[0105]
[0104] In the embodiment, the nanoparticles have a PDI of less than about 0.05, less than about 0.10, less than about 0.15, less than about 0.20, less than about 0.25, less than about 0.30, less than about 0.35, less than about 0.40, less than about 0.45, less than about 0.50, less than about 0.55, less than about 0.60, less than about 0.65, less than about 0.70, less than about 0.75, less than about 0.80, less than about 0.85, less than about 0.90, less than about 0.95, or less than about 1.0.
[0106]
[0105] In the embodiment, the nanoparticles have a PDI in the range of about 0.05 to about 1.00, about 0.06 to about 0.9, about 0.07 to about 0.8, about 0.08 to about 0.7, about 0.09 to about 0.6, or about 0.1 to about 0.5.
[0107]
[0106] In some embodiments, the nanoparticles have a PDI of about 0.05 to about 0.15, about 0.06 to about 0.14, about 0.07 to about 0.13, about 0.08 to about 0.12, or about 0.09 to about 0.11. In some embodiments, the nanoparticles have a PDI of about 0.05, about 0.06, about 0.07, about 0.08, about 0.09, about 0.10, about 0.11, about 0.12, about 0.13, about 0.14, or about 0.15.
[0108] polymer
[0107] In some embodiments, the nanoparticles further include polymers selected from the group consisting of chitosan, gelatin, sodium alginate, albumin, poly-L-lactide (PLLA), poly(lactic acid) (PLA), poly(glycolic acid) (PGA), polylactic acid glycolic acid copolymer (PLGA), polycaprolactone, polylactic acid caprolactone copolymer, poly(methyl methacrylates), poloxamer, poly(ethylene glycol) (PEG), PEG-PLLA, PEG-PLGA, poly(methyl vinyl ether / maleic anhydride), cellulose acetate phthalate, and combinations thereof.
[0109]
[0108] In some embodiments, the polymer is a lipid selected from the group consisting of lipids, polymer-lipid conjugates, carbohydrate-lipid conjugates, peptide-lipid conjugates, protein-lipid conjugates, and combinations thereof. In some embodiments, the lipid may include one or more of the following: phospholipids such as phosphatidylcholine, phosphatidylserine, phosphatidylinositide, phosphatidylethanolamine, phosphatidylglycerin, and phosphatidic acid; sphingolipids such as sphingomyelin, ceramide, phytoceramide, and cerebroside; sterols such as cholesterol, desmosterol, latesterol, stigmasterol, zymosterol, and diosgenin, and combinations thereof.
[0110]
[0109] In some embodiments, the polymer is bound to a lipid to form a polymer-lipid conjugate, where the polymer bound to the polar head group of the lipid may include polyethylene glycol, polyoxazoline, polyglutamine, polyasparagine, polyaspartamide, polyacrylamide, polyacrylate, polyvinylpyrrolidone, or polyvinyl methyl ether.
[0111]
[0110] In some embodiments, the polymer is a carbohydrate-lipid conjugate, where the carbohydrate is bound to a lipid and may include monosaccharides (such as glucose, fructose, glyceraldehyde), disaccharides, oligosaccharides, or glycosaminoglycans (such as hyaluronic acid, keratan sulfate, heparin sulfate, or chondroitin sulfate), carrageenan, extracellular polysaccharides of microorganisms, alginates, chitosan, pectin, chitin, cellulose, or starch.
[0112]
[0111] In one embodiment, the phospholipids are dipalmitoylphosphatidylcholine (DPPC), 1-palmitoyl-2-hydroxy-sn-glycero-3-phosphocholine (MPPC), 1-myristoyl-2-stearoyl-sn-glycero-3-phosphocholine (MSPC), 1,2-dimyristyl-sn-glycero-3-phosphocholine (DMPC), 1,2-dimyristyl-sn-glycero-3-phosphorylglycerol (DMPG), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine (DSPE), and 1,2-dioleoyl-sn-glycero-3-phosphocholine The following are selected from the group consisting of phosphorus (DOPC), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), 1,2-dipalmitoyl-sn-glycero-3-phospho(1'-rac-glycerol) (DPPG), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), distearoylphosphoethanolamine conjugated with polyethylene glycol (DSPE-PEG), phosphatidylserine (PS), phosphatidylethanolamine (PE), phosphatidylglycerin (PG), phosphatidylcholine (PC), and combinations thereof. In embodiments, the particles contain lipids selected from the group consisting of DPPC, MPPC, PEG, DMPC, DMPG, DSPE, DOPC, DOPE, DPPG, DSPC, DSPE-PEG, MSPC, cholesterol, PS, PC, PE, PG, and combinations thereof.
[0113]
[0112] In some embodiments, the lipid is 1,2-dipalmitoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (DPPG); 1,2-distearoyl-sn-glycero-3-phosphoglycerol, sodium salt (DSPG); 1,2-dimyristol-sn-glycero-3-phospho-L-serine sodium salt (DMPS, 14:0 PS); 1,2-dipalmitoyl-sn-glycero-3-phosphoserine, sodium salt (DPPS, 16:0 PS); 1,2-distearoyl-sn-glycero-3-phospho-L-serine (sodium salt) (DSPS, 18:0 PS); 1,2-dimyristol-sn-glycero-3-phosphate, sodium salt (DMPA, 14:0 PA); 1,2-Dipalmitoyl-sn-glycero-3-phosphate, sodium salt (DPPA, 16:0 PA); 1,2-Distearoyl-sn-glycero-3-phosphate, sodium salt (DSPA, 18:0); 1',3'-Bis[1,2-Dipalmitoyl-sn-glycero-3-phospho]-glycerol sodium salt (16:0 Cardiolipin); 1,2-Dimyristoyl-sn-glycero-3-phosphoethanolamine (DMPE, 12:0 PE); 1,2-Dipalmitoyl-sn-glycero-3-phosphoethanolamine (DPPE, 16:0); 1,2-Diarachidyl-sn-glycero-3-phosphoethanolamine (20:0 PE); 1-Stearoyl-2-Linoleoyl-sn-Glycero-3-Phosphoethanolamine; 1,2-Diheptadecanoyl-sn-Glycero-3-Phosphocholine (17:0 PC); 1,2-Dinonadecanoyl-sn-Glycero-3-Phosphocholine (19:0 PC); 1,2-Diarachidoyl-sn-Glycero-3-Phosphocholine (20:0 PC); 1,2-Diheneicosanoyl-sn-Glycero-3-Phosphocholine (21:0 PC); 1,2-Dibehenoyl-sn-Glycero-3-Phosphocholine (22:0 PC); 1,2-Ditricosanoyl-sn-Glycero-3-Phosphocholine (23:0 PC); 1,2-Dilignoceroyl-sn-Glycero-3-Phosphocholine (24:0 PC); 1-Myristoyl-2-stearoyl-sn-glycero-3-phosphocholine (14:0~18:0 PC);Selected from the group consisting of 1-stearoyl-2-palmitoyl-sn-glycero-3-phosphocholine (16:0~18:0 PC) and combinations thereof.
[0114]
[0113] In some embodiments, the polymer is a biocompatible polymer. In some embodiments, the polymer is a biodegradable polymer.
[0115]
[0114] In some embodiments, the polymer is PDMS (poly(dimethylsiloxane) (PDMS)), polydioxanone, polyglecapron, polypropylene, polyvinylidene fluoride, polyethylene terephthalate, polyethylene, e.g., ultra-high molecular weight polyethylene (UHMWPE), cross-linked UHMWPE, low-density polyethylene (LDPE), high-density polyethylene (HDPE), polyketone, polystyrene, polyvinyl chloride, poly(meth)acrylamide, polyetheretherketone (PEEK), poly(methyl methacrylate), polyester, e.g., polyglycolic acid copolymer (PLGA), polyglycolic acid (PGA), polylactic acid (PLA), polycaprolactone (PCL), poly(trimethylene carbonate), poly(α-ester), poly The following are selected from the group consisting of urethane, poly(allylamine hydrochloride), poly(esteramide), poly(orthoester), polyanhydride, poly(anhydride-co-imide), crosslinked polyanhydride, pseudo-poly(amino acid), poly(alkylcyanoacrylate), polyphosphoester, polyphosphazene, chitosan, collagen, gelatin, natural or synthetic poly(amino acid), elastin, elastin-linked polypeptide, albumin, fibrin, polysiloxane, polycarbosiloxane, polysilazane, polyalkoxysiloxane, polysaccharide, crosslinkable polymer, thermoresponsive polymer, thermo-thinning polymer, thermo-thickening polymer, block copolymer containing polyethylene glycol, and combinations thereof.
[0116]
[0115] In some embodiments, the polymer is selected from the group consisting of PGA, PLA, PLGA, polydioxanone, polycaprolactone, and combinations thereof.
[0117]
[0116] In some embodiments, the polymer is present in concentrations of approximately 1.0 wt.%, 1.5 wt.%, 2.0 wt.%, 2.5 wt.%, 3.0 wt.%, 3.5 wt.%, 4.0 wt.%, 4.5 wt.%, 5.0 wt.%, 5.5 wt.%, 6.0 wt.%, 6.5 wt.%, 7.0 wt.%, and 7.5 wt. %, approximately 8.0 wt.%, approximately 8.5 wt.%, approximately 9.0 wt.%, approximately 9.5 wt.%, approximately 10.0 wt.%, approximately 10.5 wt.%, approximately 11.0 wt.%, approximately 11.5 wt.%, approximately 12.0 wt.%, approximately 12.5 wt.%, approximately 13.0 wt.%, approximately 13.5 wt.%, approximately 14.0 wt.%, approximately 14.5 wt.%, approximately 15.0 wt.%, approximately 15.5 wt.%, approximately 16.0 wt.%, approximately 16.5 wt.%, approximately 17.0 wt.%, approximately 17.5 wt.%, approximately 18.0 wt.%, approximately 18.5 wt.%, approximately 19.0 wt.%, approximately 19.5 wt.%, or approximately 20.0 wt.%, approximately 25.0 wt.%, approximately 30.0 wt.%, approximately 35.0 wt.%, approximately 40.0 wt.%, approximately 45.0 wt. The polymer is present in weight percentages of the total weight of nanoparticles selected from the group consisting of approximately 1 wt.% to approximately 50.0 wt.%, approximately 55.0 wt.%, approximately 60.0 wt.%, approximately 65.0 wt.%, approximately 70.0 wt.%, approximately 75.0 wt.%, approximately 80.0 wt.%, approximately 85.0 wt.%, approximately 90.0 wt.%, approximately 95.0 wt.%, and approximately 99.0 wt.%. In some embodiments, the polymer is present in weight percentages of the total weight of nanoparticles in the range of approximately 1 wt.% to approximately 99 wt.%, approximately 10.0 wt.% to approximately 95.0 wt.%, approximately 50.0 wt.% to approximately 95.0 wt.%, approximately 25.0 wt.% to approximately 90.0 wt.%, or approximately 75.0 wt.% to approximately 90.0 wt.%.
[0118] Hydrogel
[0117] In some embodiments, the nanoparticles further include a hydrogel selected from the group consisting of poly(propylene oxide), poly(ethylene oxide), poloxamer (pluronic), chitosan, gelatin, cellulose derivatives, glycol chitin, poly(N-isopropylacrylamide) (PNIPAAm), PEG-PLGA-PEG, poly(D,L-lactide)-poly(ethylene glycol)-poly(D,L-lactide) (PDLLA-PEG-PDLLA), and combinations thereof. In some embodiments, the hydrogel includes chitosan and glycol chitosan. In some embodiments, the hydrogel includes glycol chitin. In some embodiments, the hydrogel is an amphiphilic block copolymer comprising at least one hydrophobic polymer block and at least one hydrophilic polymer block. In some embodiments, the amphiphilic block copolymer is PEG-PLGA-PEG or PDLLA-PEG-PDLLA.
[0119] additives
[0118] In some embodiments, the nanoparticles further include a heat stabilizer. Examples of useful heat stabilizers include phenolic antioxidants such as butylated hydroxytoluene (BHT), 2-t-butylhydroquinone, and 2-t-butylhydroxyanisole.
[0120]
[0119] In some embodiments, the nanoparticles further comprise one or more surfactants. In some embodiments, the surfactants may comprise cationic, amphoteric, or nonionic surfactants, or combinations thereof. In some embodiments, the surfactants comprise anionic surfactants selected from the group consisting of fatty acid salts, bile salts, phospholipids, carnitine, ether carboxylates, succinyl monoglycerides, mono / diacetylated tartrates of mono and diglycerides, citrates of mono and diglycerides, sodium oleate, sodium lauryl sulfate, sodium lauryl sarcosinate, sodium dioctyl sulfosuccinate (SDS), sodium cholate, sodium taurocholate, lauroyl carnitine, palmitoyl carnitine, myristoyl carnitine, lactyl esters of fatty acids, and combinations thereof. In some embodiments, the anionic surfactant comprises sodium di-(2-ethylhexyl) sulfosuccinate. In some embodiments, the surfactant is a nonionic surfactant selected from the group consisting of propylene glycol fatty acid esters, mixtures of propylene glycol fatty acid esters and glycerin fatty acid esters, triglycerides, sterols and sterol derivatives, sorbitan fatty acid esters and polyethylene glycol sorbitan fatty acid esters, sugar esters, polyethylene glycol alkyl ethers and polyethylene glycol alkylphenol ethers, polyoxyethylene-polyoxypropylene block copolymers, lower alcohol fatty acid esters, and combinations thereof. In some embodiments, the surfactant may include fatty acids. Examples of fatty acids include caprylic acid, undecylic acid, lauric acid, tridecylic acid, myristic acid, palmitic acid, stearic acid, or oleic acid. In some embodiments, the surfactant includes amphoteric surfactants, including (1) substances classified as simple proteins, complex proteins and derived proteins such as albumin, gelatin, and glycoproteins, and (2) substances included in the classification of phospholipids, such as lecithin. Amine salts and quaternary ammonium salts in cationic groups also constitute useful surfactants.
[0121]
[0120] In some embodiments, the surfactant includes a hydrophilic amphiphilic surfactant polyoxyethylene (20) sorbitan monolaurate (TWEEN® 20) or polyvinyl alcohol, which improves the distribution of the IR absorbent material in the polymer carrier. In some embodiments, when the IR absorbent material is hydrophilic and the polymer carrier is hydrophobic, the surfactant includes an amphiphilic surfactant. In some embodiments, the surfactant is an anionic surfactant bis(tridecyl) sodium sulfosuccinate (Aerosol® TR-70). In some embodiments, the surfactant is bis(tridecyl) sodium sulfosuccinate or sodium dodecyl sulfate (SDS).
[0121] In the embodiment, the surfactant is selected from the group consisting of polysorbate, polyvinyl alcohol, methylcellulose, gelatin, albumin, poloxamer, ethylcellulose, crosslinked polyacrylic acid polymer, tocopheryl polyethylene glycol succinate (TPGS), sodium cholate, lipids, stearic acid, and combinations thereof.
[0122] Pharmaceutical composition
[0122] In some embodiments, the present disclosure provides a pharmaceutical composition comprising a BTK inhibitor compound for treating an ophthalmic disease, wherein the ophthalmic disease includes inflammation of the eye, dry eye disease (including depressive dry eye disease, evaporative dry eye disease, and mixed depressive and evaporative dry eye disease), uveitis (including infectious uveitis, non-infectious uveitis, anterior uveitis, intermediate uveitis, posterior uveitis, and panuveitis), postoperative inflammation of the eye, corneal transplantation, ocular graft-versus-host disease (GVHD), allergy, allergic conjunctivitis, non-allergic conjunctivitis, and infectious conjunctivitis. The pharmaceutical composition is administered in an amount effective to treat the ophthalmic disease.
[0123]
[0123] In some embodiments, the present disclosure provides a pharmaceutical composition comprising a BTK inhibitor compound for reducing inflammation of the human eye in need. The pharmaceutical composition is administered in an amount effective to reduce inflammation of the human eye.
[0124]
[0124] In some embodiments, the present disclosure provides a pharmaceutical composition comprising the step of administering a BTK inhibitor compound to a human being for reducing the immune response of a human being having an ophthalmic disease and requiring such reduction. The immune response includes innate immune responses, adaptive immune responses, or both. Ophthalmic diseases include inflammation of the eye, dry eye diseases (including depressive dry eye diseases, evaporative dry eye diseases, and mixed depressive and evaporative dry eye diseases), uveitis (including infectious uveitis, non-infectious uveitis, anterior uveitis, intermediate uveitis, posterior uveitis, and panuveitis), postoperative inflammation of the eye, corneal transplantation, ocular graft-versus-host disease (GVHD), allergies, allergic conjunctivitis, non-allergic conjunctivitis, and infectious conjunctivitis. The pharmaceutical composition is administered in an amount effective to reduce the immune response of a human being having an ophthalmic disease.
[0125]
[0125] The pharmaceutical composition is typically formulated to provide a therapeutically effective amount of a BTK inhibitor or a pharmaceutically acceptable salt thereof. If desired, the pharmaceutical composition comprises the pharmaceutically acceptable salt and / or coordination compound thereof, as well as one or more pharmaceutically acceptable excipients, carriers, e.g., inert solid diluents and fillers, diluents, e.g., sterile aqueous solutions and various organic solvents, permeation enhancers, solubilizers, and auxiliaries. If desired, other components may be mixed into the formulation in addition to the BTK inhibitor or a pharmaceutically acceptable salt thereof, or the two components may be formulated into separate formulations for use separately or in combination.
[0126]
[0126] In selected embodiments, the concentrations of the BTK inhibitor or pharmaceutically acceptable salt thereof provided in the pharmaceutical composition of the present disclosure are, for example, 100%, 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.09%, 0. Lower than 0.8%, 0.07%, 0.06%, 0.05%, 0.04%, 0.03%, 0.02%, 0.01%, 0.009%, 0.008%, 0.007%, 0.006%, 0.005%, 0.004%, 0.003%, 0.002%, 0.001%, 0.0009%, 0.0008%, 0.0007%, 0.0006%, 0.0005%, 0.0004%, 0.0003%, 0.0002%, or 0.0001% w / w, w / v, or v / v.
[0127]
[0127] In selected embodiments, the concentrations of the BTK inhibitor or pharmaceutically acceptable salt thereof provided in the pharmaceutical composition of the Disclosure are 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20%, 19.75%, 19.50%, 19.25%, 19%, 18.75%, 18.50%, 18.25%, 18%, 17.75%, 17.50%, 17.25%, 17%, 16.75%, 16.50%, 16.25%, 16%, 15.75%, 15.50%, 15.25%, 15%, 14.75%, 14.50%, 14.25%, 14%, 13.75%, 13.50%, 13.25%. 13%, 12.75%, 12.50%, 12.25% 12%, 11.75%, 11.50%, 11.25% 11%, 10.75%, 10.50%, 10.25% 10%, 9.75%, 9.50%, 9.25% 9%, 8.75%, 8.50%, 8.25% 8%, 7.75%, 7.50%, 7.25% 7%, 6.75%, 6.50%, 6.25% 6%, 5.75%, 5.50%, 5.25% 5%, 4.75%, 4.50%, 4.25%, 4%, 3.75%, 3.50%, 3.25%, 3%, 2.75%, 2.50%, 2.25%, 2%, 1.75%, 1.50%, 125%, 1%, 0.5%, 0.4%, 0.3%, 0.2%, 0.1%, 0.09%, 0.08%, 0.07%, 0.06%, 0.05%, 0.04%, 0.03%, 0.02%, 0.0 Higher than 1%, 0.009%, 0.008%, 0.007%, 0.006%, 0.005%, 0.004%, 0.003%, 0.002%, 0.001%, 0.0009%, 0.0008%, 0.0007%, 0.0006%, 0.0005%, 0.0004%, 0.0003%, 0.0002%, or independently higher than 0.0001% w / w, w / v, or v / v.
[0128]
[0128] In the selected embodiment, the concentrations of the BTK inhibitor or its pharmaceutically acceptable salt are approximately 0.0001% to approximately 50%, approximately 0.001% to approximately 40%, approximately 0.01% to approximately 30%, approximately 0.02% to approximately 29%, approximately 0.03% to approximately 28%, approximately 0.04% to approximately 27%, approximately 0.05% to approximately 26%, approximately 0.06% to approximately 25%, approximately 0.07% to approximately 24%, and approximately 0.08%. The percentages are independently located in the ranges of approximately 23% (%~23%), 22% (approximately 0.09%), 21% (approximately 0.1%), 20% (approximately 0.2%), 19% (approximately 0.3%), 18% (approximately 0.4%), 17% (approximately 0.5%), 16% (approximately 0.6%), 15% (approximately 0.7%), 14% (approximately 0.8%), 12% (approximately 0.9%), or 1% (approximately 1%) in the ranges of w / w, w / v, or v / v.
[0129]
[0129] In the selected embodiment, the concentration of the BTK inhibitor or its pharmaceutically acceptable salt is independently in the range of approximately 0.001% to approximately 10%, approximately 0.01% to approximately 5%, approximately 0.02% to approximately 4.5%, approximately 0.03% to approximately 4%, approximately 0.04% to approximately 3.5%, approximately 0.05% to approximately 3%, approximately 0.06% to approximately 2.5%, approximately 0.07% to approximately 2%, approximately 0.08% to approximately 1.5%, approximately 0.09% to approximately 1%, and approximately 0.1% to approximately 0.9% w / w, w / v, or v / v.
[0130]
[0130] In the selected embodiment, the amounts of the BTK inhibitor or its pharmaceutically acceptable salt are 10g, 9.5g, 9.0g, 8.5g, 8.0g, 7.5g, 7.0g, 6.5g, 6.0g, 5.5g, 5.0g, 4.5g, 4.0g, 3.5g, 3.0g, 2.5g, 2.0g, 1.5g, 1.0g, 0.95g, 0.9g, 0.85g, 0.8g, 0.75g, 0.7g, 0.65g, 0.6g, 0.55g, 0.5g, 0.45g, 0.4g, 0.35g, 0.3g, 0.25g, and 0.2g. , 0.15g, 0.1g, 0.09g, 0.08g, 0.07g, 0.06g, 0.05g, 0.04g, 0.03g, 0.02g, 0.01g, 0.009g, 0.008g, 0.007g, 0.006g, 0.005g, 0.004g, 0.003g, 0.002g, 0.001g, 0.0009g, 0.0008g, 0.0007g, 0.0006g, 0.0005g, 0.0004g, 0.0003g, 0.0002g, or 0.0001g are independently equal to or less than these amounts.
[0131]
[0131] In the selected embodiment, the amounts of the BTK inhibitor or its pharmaceutically acceptable salt are 0.0001g, 0.0002g, 0.0003g, 0.0004g, 0.0005g, 0.0006g, 0.0007g, 0.0008g, 0.0009g, 0.001g, 0.0015g, 0.002g, 0 .0025g, 0.003g, 0.0035g, 0.004g, 0.0045g, 0.005g, 0.0055g, 0.006g, 0.0065g, 0. 007g, 0.0075g, 0.008g, 0.0085g, 0.009g, 0.0095g, 0.01g, 0.015g, 0.02g, 0.025g, 0.03g, 0.035g, 0.04g, 0.045g, 0.05g, 0.055g, 0.06g, 0.065g, 0.07g, 0.075g, 0.0 8g, 0.085g, 0.09g, 0.095g, 0.1g, 0.15g, 0.2g, 0.25g, 0.3g, 0.35g, 0.4g, 0.45g, 0. Any amount greater than 5g, 0.55g, 0.6g, 0.65g, 0.7g, 0.75g, 0.8g, 0.85g, 0.9g, 0.95g, 1g, 1.5g, 2g, 2.5g, 3g, 3.5g, 4g, 4.5g, 5g, 5.5g, 6g, 6.5g, 7g, 7.5g, 8g, 8.5g, 9g, 9.5g, or 10g.
[0132]
[0132] BTK inhibitors or pharmaceutically acceptable salts thereof are effective over a wide range of dosages. For example, in the treatment of adult humans, independently available dosages range from 0.01 to 1000 mg per day, 0.5 to 100 mg per day, 1 to 50 mg per day, and 5 to 40 mg per day. The exact dosage depends on the route of administration, the form of the compound, the sex and age of the person being treated, the weight of the person being treated, and the preference and experience of the attending physician.
[0133]
[0133] Pharmaceutical compositions may be provided in various forms, including tablets, gelatin capsules, sugar-coated tablets, syrups, suspensions, solutions, powders, granules, emulsions, or suspensions of fine particles or nanoparticles for controlled release or suspensions of lipids or polymeric vesicles.
[0134]
[0134] In embodiments, the BTK inhibitor compound is a dosage form selected from a solution, suspension, emulsion, microemulsion, ointment, gel, hydrogel, drug delivery device, tablet, or capsule. In embodiments, the drug delivery device is an intraocular implant for sustained release of the BTK inhibitor compound. The intraocular implant includes solid and semi-solid devices, usually made of polymer material, containing the BTK inhibitor. In embodiments, the dosage form is a sustained-release form, a long-release form, a controlled-release form, or a combination thereof. In embodiments, the sustained-release, long-release, or controlled-release dosage form includes a pegylated BTK inhibitor.
[0135]
[0135] In the embodiment, the BTK inhibitor compound is administered as particles that self-aggregate in the depot upon administration. In the embodiment, the particles further comprise a polymer. In the embodiment, the polymer is selected from the group consisting of chitosan, gelatin, sodium alginate, albumin, poly-L-lactide (PLLA), poly(lactic acid) (PLA), poly(glycolic acid) (PGA), polylactic acid glycolic acid copolymer (PLGA), polycaprolactone, polylactic acid caprolactone copolymer, poly(methyl methacrylates), poloxamer, poly(ethylene glycol) (PEG), PEG-PLLA, PEG-PLGA, poly(methyl vinyl ether / maleic anhydride), cellulose acetate phthalate, and combinations thereof. In the embodiment, the polymer is polylactic acid glycolic acid copolymer (PLGA), PEG-PLGA, or a combination thereof. In the embodiment, the polymer is polylactic acid glycolic acid copolymer (PLGA). In the embodiment, the polymer is PEG-PLGA. In the embodiment, the polymer is a combination of polylactic acid glycolic acid copolymer (PLGA) and PEG-PLGA. In the embodiment, the particles are administered by intravitreal injection.
[0136]
[0136] The following are non-limiting exemplary pharmaceutical compositions and methods for preparing them.
[0137] Pharmaceutical composition for topical administration
[0137] The pharmaceutical compositions for topical administration of the eye according to the present disclosure may be formulated into conventional ophthalmologically compatible vehicles, such as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, hydrogels, sprays, aerosols, or oils.
[0138]
[0138] The formulation may be one of many topical formulations containing water as a main component, including solutions, gels, hydrogels, creams, sprays, and foams. In embodiments, the formulation may be in the form of an aqueous gel. Thus, formulations of the present disclosure for topical administration of the eye may contain a gelling agent or a thickening agent. Any water-dispersible gelling agent is suitable for use in the compositions of the present disclosure. One preferred gelling agent is hydroxypropyl cellulose, such as that sold under the trademark name KLUCEL (registered trademark) (Hercules Incorporated). Another preferred gelling agent is hydroxyethyl cellulose, such as that sold under the trademark name NATROSOL (registered trademark) (Hercules Incorporated). Other suitable gelling agents include CARBOPOL (registered trademark) 934, 940, 941, 980, and 981 (BFGoodrich Co.), ETD 2020 (trademark), and ULTREZ (registered trademark) (Noveon). This includes carboxyvinyl polymers, also known as carbomers, as sold by Inc. Further suitable gelling agents are polyvinyl alcohol, polyethylene oxide, propylene glycol alginate, methylcellulose, hydroxypropyl methylcellulose, and natural polymer gums such as xanthan gum and carrageenan. The concentration of the gelling agent in the composition can be varied depending on several factors, including the desired degree of stabilization of the suspension and the desired viscosity of the gel composition.
[0139]
[0139] If desired, the formulations of the present disclosure may further include additional pharmaceutically acceptable excipients that are typically used in formulations and known to those skilled in the art. Such excipients include, for example, wetting agents, emollients, pH stabilizers, preservatives, chelating agents, and antioxidants.
[0140]
[0140] Formulations of the present disclosure for topical administration to the eye can be manufactured by any means by which the components of the present disclosure are combined to provide a pharmaceutical formulation. For example, a suspension of benzoyl peroxide can be prepared by combining water, a water-miscible organic solvent, and benzoyl peroxide. Preferably, the combination is mixed by stirring, sonication, grinding, and / or shaking to prepare a homogeneous suspension of benzoyl peroxide in water and an organic solvent. Additional components such as gelling agents and other excipients may be added either before or after the homogeneous suspension is obtained.
[0141]
[0141] Gels containing polymers can swell in water and then interact with the water to thicken it, thereby increasing its viscosity. Polymers may interact physically by chain entanglement or by ionic or hydrophobic / hydrophilic interactions. In each case, the polymers form a matrix that increases the viscosity of water, enabling (1) physical stabilization and prevention of migration of suspended BTK inhibitors, (2) maintenance of product homogeneity during storage, (3) clean, drip-free, and stain-free transfer of the product from the primary packaging to the skin surface, and (4) easy spreading and acceptable aesthetics.
[0142]
[0142] In embodiments, the composition for topical administration of the eye comprises a matrix builder, such as high molecular weight polyvinylpyrrolidone (e.g., Kollidon® 90F), a thickening polymer and a biopolymer; poloxamer, an emulsifier, an oil that stably suspends in a gel, and a solvent. The composition for topical administration of the eye may also have a sensory modifier such as isopropyl myristate. Solubility in an aqueous matrix can be increased by using a water-miscible solvent such as propylene glycol, polyethylene glycol, triacetin, poloxamer, and low molecular weight polyvinylpyrrolidone.
[0143]
[0143] In the embodiment, the composition for topical administration to the eye comprises a BTK inhibitor suspended in a hydrogel. The hydrogel is a colloidal gel formed as a dispersion in water or another aqueous medium. Thus, the hydrogel is formed when a dispersed phase (polymer) combines with a continuous phase (i.e., water) to form a colloid that produces a viscous, jelly-like product, such as solidified silicic acid. The hydrogel is a three-dimensional network of hydrophilic polymer chains crosslinked by either chemical or physical bonds. Due to the hydrophilic nature of the polymer chains, the hydrogel absorbs water and swells (unless it has already absorbed its maximum amount of water). The swelling process is the same as the dissolution of a non-crosslinked hydrophilic polymer. By definition, water constitutes at least 10% of the total weight (or volume) of the hydrogel.
[0144]
[0144] Examples of hydrogels include polyhydroxyethyl methacrylate and synthetic polymers such as chemically or physically crosslinked polyvinyl alcohol, polyacrylamide, poly(N-vinylpyrrolidone), polyethylene oxide, and hydrolyzed polyacrylonitrile. Examples of hydrogels that are organic polymers include covalently or ionically crosslinked polysaccharide-based hydrogels, such as alginic acid, pectin, carboxymethylcellulose, heparin, polyvalent metal salts of hyaluronic acid, and hydrogels from chitin, chitosan, pullulan, gellan, and xanthan gum. Preferred hydrogels include cellulose compounds (i.e., hydroxypropyl methylcellulose [HPMC]) and / or high molecular weight hyaluronic acid (HA).
[0145]
[0145] The pharmaceutical compositions for topical administration of the eye according to this disclosure may also include wetting agents; mucosal adhesion agents; flavor enhancers; preservatives such as parahydroxybenzoic acid esters; stabilizers; moisture adjusters; pH adjusters; osmotic pressure adjusters; emulsifiers; UV-A and UV-B shielding agents; and inert additives or combinations thereof, such as antioxidants such as α-tocopherol, butylhydroxyanisole or butylhydroxytoluene, superoxide dismutase, ubiquinol, or certain metal chelating agents.
[0146]
[0146] Sterilized formulations for topical ophthalmic administration are packaged, stored, and ready for immediate use. In exemplary embodiments, the formulation is in drop form, in a manner typically used for applying eye drops. Conventional squeeze-type dropper dispensers are perfectly suited for use in the application of the ophthalmic formulations of this disclosure. In exemplary embodiments, the formulation is conveniently administered by dropping the formulation into the affected (one or more) eyes of the user.
[0147]
[0147] The formulations of the present disclosure for topical administration of the eye, comprising a preservative, are particularly advantageous for use in a multi-dose container. A multi-dose container, as used herein, refers to a container that allows the ophthalmic formulation present in the container to be applied two or more times separately. Such a container is resealable, i.e., the cap of the container can be removed for a first application, and then the cap can be put back on the container, thereby providing a substantially liquid-impermeable seal again. In various exemplary embodiments, the antimicrobial preservative is present in an amount sufficient to reduce the microbial concentration over a period of about 12 hours to about 1 month, e.g., about 12 hours to about 3 weeks, e.g., about 12 hours to about 2 weeks, e.g., about 12 hours to about 1 week, e.g., about 12 hours to about 3 days, e.g., about 12 hours to about 48 hours, e.g., about 12 hours to about 24 hours.
[0148]
[0148] In exemplary embodiments, these preservative-free formulations may be packaged in unit-dose containers, i.e., only a single dose may be provided by a given container. With such preservative-free compositions, once the consumer first opens the container, microbial growth becomes uncontrollable. Therefore, the consumer is instructed to discard the container after the first dose. Suitable unit-dose systems, such as a mold-and-fill unit-dose preservative-free packaging system, are typically used for preservative-free formulations.
[0149]
[0149] Typical concentrations of BTK inhibitors or pharmaceutically acceptable salts thereof for topical administration to the eye are approximately 0.01% to 10.0% by weight, approximately 0.02% to 9.0% by weight, approximately 0.03% to 8.0% by weight, approximately 0.04% to 7.0% by weight, approximately 0.05% to 8.0% by weight, approximately 0.06% to 7.0% by weight, approximately 0.07% to 6.0% by weight, approximately 0.08% to 5.0% by weight, approximately 0.09% to 4.0% by weight, approximately 0.1% to 3.0% by weight, approximately 0.2% to 2.0% by weight, approximately 0.3% to 1.0% by weight, approximately 0.4% to 5.0% by weight, or approximately 0.5% to 5.0% by weight.
[0150]
[0150] Typical concentrations of BTK inhibitors or pharmaceutically acceptable salts thereof for topical administration to the eye are approximately 0.01% by weight, approximately 0.02% by weight, approximately 0.03% by weight, approximately 0.04% by weight, approximately 0.05% by weight, approximately 0.06% by weight, approximately 0.07% by weight, approximately 0.08% by weight, approximately 0.09% by weight, approximately 0.10% by weight, approximately 0.15% by weight, approximately 0.20% by weight, approximately 0.25% by weight, approximately 0.30% by weight, and approximately 0. This is approximately 35% by weight, 0.40% by weight, 0.45% by weight, 0.50% by weight, 0.55% by weight, 0.6% by weight, 0.65% by weight, 0.7% by weight, 0.75% by weight, 0.8% by weight, 0.85% by weight, 0.9% by weight, 0.95% by weight, 1% by weight, 2% by weight, 3% by weight, 4% by weight, 5% by weight, 6% by weight, 7% by weight, 8% by weight, 9% by weight, or 10% by weight.
[0151]
[0151] In various exemplary embodiments, the BTK inhibitor or a pharmaceutically acceptable salt thereof is present in concentrations of about 0.1 to about 10% w / v, for example, about 0.1 to about 4.5% w / v, for example, about 0.1 to about 4.0% w / v, for example, about 0.1 to about 3.5% w / v, for example, about 0.1 to about 3.0% w / v, for example, about 0.1 to about 2.5% w / v, for example, about 0.1 to about 2.0% w / v, for example It is used at concentrations of approximately 0.1 to 1.5% w / v, for example, approximately 0.1 to 1.0% w / v, for example, approximately 0.1 to 0.8% w / v, for example, approximately 0.1 to 0.7% w / v, for example, approximately 0.1 to 0.6% w / v, for example, approximately 0.1 to 0.5% w / v, for example, approximately 0.1 to 0.4% w / v, for example, approximately 0.1 to 0.3% w / v, and for example, approximately 0.1 to 0.2% w / v.
[0152]
[0152] A formulation for local administration to the eye may be optionally provided, and may contain a tonic modifier.
[0153]
[0153] In exemplary embodiments, the tonicity modifier is nonionic. The tonicity modifier can be selected from, but is not limited to, mannitol, sorbitol, dextrose, sucrose, urea, glycerin, polyethylene glycol, and any mixture thereof. In exemplary embodiments, the tonicity modifier is present in an amount sufficient to produce a tonicity of about 250 to 350 milliosmoles (mOsmol / kg) per kilogram, for example, about 265 to about 325 mOsmol / kg, for example, about 280 to about 310 mOsmol / kg, for example, about 295 to about 315 mOsmol / kg.
[0154]
[0154] Preparations for topical administration to the eye may, but are not limited to, contain an ionic salt selected from alkali metal halides (e.g., NaCl, KCl, NaBr, etc.) in an amount ranging from about 0.3% to about 1% by weight, or in an amount sufficient to approximate the salt concentration and / or tonicity of human tears. Salts selected from this group are sometimes called ionic tonic modifiers.
[0155]
[0155] When preservatives are used in formulations for topical administration to the eye, the antimicrobial agent is present in an amount sufficient to create a microbial barrier that maintains or reduces microbial concentration over a period of approximately 12 hours to approximately 1 month, for example, approximately 12 hours to approximately 3 weeks, for example, approximately 12 hours to approximately 2 weeks, for example, approximately 12 hours to approximately 1 week, for example, approximately 12 hours to approximately 3 days, for example, approximately 12 hours to approximately 48 hours, for example, approximately 12 hours to approximately 24 hours. Suitable preservatives include, but are not limited to, benzalkonium chloride, benzyl alcohol, sorbic acid, chlorobutanol, cetrimonium, methylparaben, propylparaben, polyaminopropyl biguanide, phenylethyl alcohol, chlorhexidine, chlorhexidine digluconate, chloroquat, stabilized oxychloro complex, or any combination thereof.
[0156]
[0156] Buffers that may be used in formulations for topical administration to the eye include, but are not limited to, buffers prepared from sodium, potassium bicarbonate, phosphates, acetates, citrates, borates, and / or phosphoric acid, acetic acid, citric acid, or boric acid. In exemplary embodiments, the buffer is sodium dihydrogen phosphate, or disodium phosphate, or boric acid / sodium borate. The buffers of the Disclosure are present in an amount sufficient to produce and maintain formulation pH including pH about 5.0 to about 8.0, e.g., about 5.5 to about 7.7, e.g., about 6.0 to about 7.5, e.g., about 6.3 to about 7.5, e.g., about 6.7 to about 7.1, and pH about 5.7, about 5.9, about 6.1, about 6.3, about 6.5, about 6.7, about 6.9, about 7.1, about 7.3, about 7.5, about 7.7, or about 7.9.
[0157]
[0157] Surfactants may also be added to the composition for topical administration to the eye. In exemplary embodiments, the surfactant is present in a concentration range of about 0.001% to about 0.3%, for example, about 0.005% to about 0.2%, for example, about 0.01% to about 0.1%, for example, about 0.05% to about 0.1%, in order to enhance the wetting properties of the formulation. Surfactants may include, but are not limited to, poloxamer, polysorbate 80, polysorbate 20, tyroxapole, polyoxyethylene, bridge 35, bridge 58, bridge 78, Aptet 100, G1045, span 20, 40, and 85, tween 20, 40, 80, or 81, sodium lauroyl sarcosinate, lauroyl-L-glutamic acid triethanolamine, sodium myristyl sarcosinate, and sodium lauryl sulfate, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene hydrogenated castor oil, polyethylene glycol fatty acid esters (e.g., polyoxyl stearate), polyoxyethylene polyoxypropylene alkyl ethers, polyoxyalkylene alkylphenyl ethers, polyglycerin fatty acid esters (e.g., decaglycerin monolaurate), glycerin fatty acid esters, sorbitan fatty acid esters, polyoxyethylene polyoxypropylene glycol (poloxamer), polyoxyl stearate 40, and / or any combination thereof.
[0158]
[0158] Stabilizers may also be added to formulations for topical administration to the eye. Suitable stabilizers include, but are not limited to, sodium metabisulfite, sodium bisulfate, acetylcysteine, ascorbic acid, sodium thiosulfate, α-tocopherol, carnosine, retinyl palmitate, salts of ethylenediaminetetraacetic acid (EDTA) (e.g., disodium, tetrasodium, calcium, or calcium sodium edetate salt), or any combination thereof.
[0159]
[0159] When present in the formulation described, the mucosal adhesive increases corneal contact time, enhances bioavailability, and / or provides a lubricating effect, and includes, but is not limited to, acrylic acid polymers, methylcellulose, ethylcellulose, povidone K-30, hydroxypropyl methylcellulose, hydroxyethylcellulose, Carbopol® polymers (e.g., (registered trademark) 674, 676, 690, 980 NF, EZ-2, EZ-3, EZ-4, Aqua 30, and Novethix® L-10), hydroxypropylcellulose, polyvinyl alcohol, gelatin, sodium chondroitin sulfate, or any combination thereof.
[0160]
[0160] In the embodiment, after administration to the surface of the eye, the composition enters the conjunctiva and anterior sclera and then the corneal layer. When a mucosal adhesive is present, the residence time in the cornea is increased, and the drug appears to diffuse slowly over time to the posterior sclera, resulting in the delivery of a sustained concentration of the BTK inhibitor or its pharmaceutically acceptable salt in the posterior sclera. The mucosal adhesive achieves this objective, for example, by delaying the loss of the drug through nasolacrimal duct drainage due to lacrimation and tear turnover. Mucosal adhesives also typically have viscosity-enhancing properties that provide a desirable sedative or lubricating effect. Optionally, penetration enhancers added to the formulation promote the penetration of the formulation into the corneal epithelial layer and further increase the residence time of the BTK inhibitor or its pharmaceutically acceptable salt in the eye. Stabilizers act as antioxidants or otherwise can delay the chemical degradation of the BTK inhibitor formulation. Buffers buffer the formulation to a comfortable near-neutral pH suitable for ocular administration. The tonicity modifier in the formulation provides the appropriate osmolality by weight for the ophthalmic preparation.
[0161]
[0161] The optional penetration enhancers present in the preparation for topical administration of the eye described above include, but are not limited to, laurocapram (Azon), bile acids and their alkali metal salts, such as chenodeoxycholic acid, cholic acid, taurocholic acid, taurodeoxycholic acid, tauroursodeoxycholic acid, or ursodeoxycholic acid, glycocholates, n-dodecyl-β-D-maltoside, sucrose dodecanoate, octylmaltoside, decylmaltoside, tridecylmaltoside, tetradecylmaltoside, hexamethylene lauramide, hexamethylene octanamide, glycerin monolaurate, PGML (polyethylene glycol monolaurate), dimethyl sulfoxide, methylsulfonylmethane, methylsulfonylmethane, sodium fusidate, saponin, cyclodextrin (CD), or any combination thereof.
[0162]
[0162] Furthermore, a solubilizer or resuspension agent may be added to the formulation for topical ocular administration. Suitable solubilizers or resuspension agents include, but are not limited to, cyclodextrins (CD), such as hydroxypropyl γ-cyclodextrin (Cavasol®), sulfobutyl ether 4β-cyclodextrin (Captisol®), and hydroxypropyl β-cyclodextrin (Kleptose®) (2-hydroxypropyl β-cyclodextrin, etc.), polysorbate 80 (Tween 80®), or hyaluronic acid or hyaluronic acid salts. In other examples, cyclodextrins are known to delay the uptake of steroid compounds (such as hydrocortisone) into ocular tissue, but cyclodextrins in particular may also exhibit penetration-enhancing properties. Masson, Proc. of the9 thIntl.Symposium on Cyclodextrins, Kluwer Academic Publishers(1999), 363~369;Loftsson, Acta Ophthalmologica Scandinavica(2003), 144~150;International Journal of Pharmaceutics156(1997), 201~209.
[0163]
[0163] A list of typical carriers, stabilizers, and adjuvants known to those skilled in the art that may be useful in the ophthalmic compositions described herein is provided in Gennaro (2005) Remington: The Science and Practice of Pharmacy, Mack Publishing, 21 st It can be found in ed.
[0164] Pharmaceutical composition for injection
[0164] Pharmaceutical compositions for injection may be formulated with pharmaceutical excipients suitable for injection. The components and amounts of the drug in the composition are as described herein.
[0165]
[0165] For injection, aqueous solutions in physiological saline have also been conventionally used. Ethanol, glycerin, propylene glycol, and liquid polyethylene glycol (and suitable mixtures thereof), as well as vegetable oils, may also be used. Appropriate fluidity can be maintained, for example, by using coating agents such as lecithin to maintain the required particle size in the case of dispersions, and by using surfactants. Prevention of microbial action may be achieved by various antimicrobial and antifungal agents, such as parabens, chlorobutanol, phenol, sorbic acid, and thimerosal.
[0166]
[0166] Sterile injectable solutions are prepared by placing the required amount of BTK inhibitor or a pharmaceutically acceptable salt thereof in a suitable solvent along with various other components listed above as needed, and then sterilizing by filtration. Generally, dispersions are prepared by placing various sterile active ingredients in a sterile vehicle containing a basic dispersion medium and other components listed above as needed. In the case of sterile powders for the preparation of sterile injectable solutions, specific preferred preparation methods are vacuum drying and freeze-drying techniques, which involve obtaining powders of the active ingredient plus any additional desired components from their pre-sterilically filtered solutions.
[0167]
[0167] BTK inhibitors, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions of these compounds may be administered by any means that allows the compound to be delivered to the site of action. These methods include oral routes, intraduodenal routes, parenteral injection (including intravenous, intra-arterial, subcutaneous, intramuscular, intravascular, intraperitoneal, or intravenous infusion), topical administration (e.g., perdermal), rectal administration, local delivery via catheter or stent, or by inhalation. The compounds may also be administered intraadiposally or intrathecally.
[0168]
[0168] In the embodiment, the pharmaceutical composition comprising a BTK inhibitor or a pharmaceutically acceptable salt thereof is administered by intravitreal injection.
[0169]
[0169] In the embodiment, the pharmaceutical composition containing a BTK inhibitor or a pharmaceutically acceptable salt thereof is administered by intraocular injection.
[0170]
[0170] Exemplary parenteral administration forms include a solution or suspension of the active compound in a sterile aqueous solution, such as an aqueous solution of propylene glycol or an aqueous solution of dextrose. Such dosage forms may be appropriately buffered if desired.
[0171]
[0171] This disclosure also provides kits. The kits include a pharmaceutical composition comprising a BTK inhibitor or a pharmaceutically acceptable salt thereof, either alone or in combination with appropriate packaging, and materials that may include instructions for use, a review of clinical trials, and a list of adverse events. Such kits may also include information that demonstrates or proves the activity and / or benefits of the composition, and / or information describing dosing, administration, adverse events, drug interactions, or other information useful to healthcare providers, such as references to scientific literature, package inserts, results of clinical trials, and / or summaries thereof. Such information may be based on various studies, such as studies using experimental animals, including in vivo models, and studies based on human clinical trials. The kits may further include other pharmaceutically active ingredients. Appropriate packaging and additional articles for use (e.g., measuring cups for liquid preparations, foil packaging to minimize exposure to air, etc.) are known in the art and may be included in the kits. The kits described herein may be provided to, sold, and / or promoted to healthcare providers, including physicians, nurses, pharmacists, and prescribing officials. In selected embodiments, the kits may also be sold directly to consumers. In embodiments, this disclosure provides a kit of a pharmaceutical composition comprising a BTK inhibitor or a pharmaceutically acceptable salt thereof for use in the treatment of ophthalmic diseases described herein.
[0172] Dosage and medication plan
[0172] The dosage of BTK inhibitors or their pharmaceutically acceptable salts depends on the person being treated, the severity of the disorder or condition, the rate of administration, the properties of the compound, and the discretion of the prescribing physician. However, effective dosages range from approximately 0.001 to approximately 100 mg per kg of body weight per day, for example, from approximately 1 to approximately 35 mg / kg / day in single or divided doses. For a person weighing 70 kg, this means approximately 0.05 to 7 g / day, for example, from approximately 0.05 to approximately 2.5 g / day. In some cases, dosage levels below the lower end of the aforementioned range may be more than sufficient, while in other cases, even higher doses may be employed without causing adverse side effects, for example, by dividing such a high dose into several smaller doses for administration throughout the day.
[0173]
[0173] In some embodiments, BTK inhibitors or pharmaceutically acceptable salts thereof are administered in unit doses. Typically, such administration is by injection, e.g., intravenous or intravitreal injection, to rapidly deliver the drug. However, other routes may be used as needed. Single doses of BTK inhibitors or pharmaceutically acceptable salts thereof may also be used for the treatment of acute diseases.
[0174]
[0174] In some embodiments, the BTK inhibitor or a pharmaceutically acceptable salt thereof is administered in multiple doses to treat an ophthalmic disease. In embodiments, the BTK inhibitor or a pharmaceutically acceptable salt thereof is administered in multiple doses. In embodiments, the BTK inhibitor or a pharmaceutically acceptable salt thereof is administered in multiple doses by injection, for example, intravenous injection or intravitreal injection. In embodiments, the administration may be once, twice, three, four, five, six times, or more than six times per day. In embodiments, the administration may be selected from the group consisting of once a day, twice a day, three times a day, four times a day, five times a day, six times a day, once every other day, once a week, twice a week, three times a week, four times a week, every other week, and monthly. In other embodiments, the BTK inhibitor or a pharmaceutically acceptable salt thereof is administered about once to about six times per day. In some embodiments, the BTK inhibitor or a pharmaceutically acceptable salt thereof is administered once daily; in other embodiments, the BTK inhibitor or a pharmaceutically acceptable salt thereof is administered twice daily; and in other embodiments, the BTK inhibitor or a pharmaceutically acceptable salt thereof is administered three times daily. In some embodiments, the BTK inhibitor or a pharmaceutically acceptable salt thereof is administered three times a week, including Monday, Wednesday, and Friday.
[0175]
[0175] In some embodiments, the pharmaceutical composition containing the BTK inhibitor is administered to human subjects by intravitreous or intraocular injection monthly, every other month, every three months, four times a year, every five months, every six months, or once a year. In some embodiments, the pharmaceutical composition containing the BTK inhibitor is administered to human subjects by intravitreous or intraocular injection monthly for two, three, four, or five months, and thereafter administered every other month.
[0176]
[0176] In some embodiments, the pharmaceutical composition comprising the BTK inhibitor is administered topically to human subjects once daily, twice daily, three times daily, once every other day, weekly, twice weekly, three times weekly, four times weekly, every other week, or monthly.
[0177]
[0177] Administration of a BTK inhibitor or a pharmaceutically acceptable salt thereof may be continued for as long as necessary. In some embodiments, the BTK inhibitor or a pharmaceutically acceptable salt thereof is administered for more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, or 31 days. In some embodiments, the BTK inhibitor or a pharmaceutically acceptable salt thereof is administered for less than 28, 14, 7, 6, 5, 4, 3, 2, or 1 day. In some embodiments, the BTK inhibitor or a pharmaceutically acceptable salt thereof is administered for about 14 days, about 21 days, about 28 days, about 35 days, about 42 days, about 49 days, or about 56 days. In some embodiments, BTK inhibitors or pharmaceutically acceptable salts thereof are administered continuously and chronically, for example, to treat chronic effects. In other embodiments, BTK inhibitors or pharmaceutically acceptable salts thereof are administered for less than about 7 days. In yet another embodiment, administration continues for more than about 6, 10, 14, 28 days, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, or 1 year. In some embodiments, administration continues for more than about 1 year, 2 years, 3 years, 4 years, or 5 years. In some embodiments, continuous dosing is achieved and maintained for as long as necessary.
[0178]
[0178] In some embodiments, effective doses of the BTK inhibitor or a pharmaceutically acceptable salt thereof are approximately 1 mg to 500 mg, approximately 10 mg to 300 mg, approximately 20 mg to 250 mg, approximately 25 mg to 200 mg, approximately 10 mg to 200 mg, approximately 20 mg to 150 mg, approximately 30 mg to 120 mg, approximately 10 mg to 90 mg, approximately 20 mg to 80 mg, approximately 30 mg to 70 mg, approximately 40 mg to 60 mg, and approximately 45 mg to 55 mg. The ranges are approximately 48mg to 52mg, 50mg to 150mg, 60mg to 140mg, 70mg to 130mg, 80mg to 120mg, 90mg to 110mg, 95mg to 105mg, 150mg to 250mg, 160mg to 240mg, 170mg to 230mg, 180mg to 220mg, 190mg to 210mg, 195mg to 205mg, or 198mg to 202mg. In some embodiments, effective doses of the BTK inhibitor or a pharmaceutically acceptable salt thereof are approximately 15 mg, 25 mg, 30 mg, 50 mg, 50 mg, 75 mg, 90 mg, 100 mg, 120 mg, 125 mg, 150 mg, 175 mg, 180 mg, 200 mg, 225 mg, 240 mg, 250 mg, 275 mg, 300 mg, 325 mg, 350 mg, 360 mg, 375 mg, 400 mg, 425 mg, 450 mg, 475 mg, 480 mg, or 500 mg. In some embodiments, effective doses of the BTK inhibitor or a pharmaceutically acceptable salt thereof are 15 mg, 25 mg, 30 mg, 50 mg, 60 mg, 75 mg, 90 mg, 100 mg, 120 mg, 150 mg, 175 mg, 180 mg, 200 mg, 225 mg, 240 mg, 250 mg, 275 mg, 300 mg, 325 mg, 350 mg, 360 mg, 375 mg, and 480 mg.
[0179]
[0179] In some embodiments, effective doses of a BTK inhibitor or a pharmaceutically acceptable salt thereof are approximately 0.01 mg / kg to approximately 4.3 mg / kg, approximately 0.15 mg / kg to approximately 3.6 mg / kg, approximately 0.3 mg / kg to approximately 3.2 mg / kg, approximately 0.35 mg / kg to approximately 2.85 mg / kg, approximately 0.15 mg / kg to approximately 2.85 mg / kg, approximately 0.3 mg to approximately 2.15 mg / kg, approximately 0.45 mg / kg to approximately 1.7 mg / kg, approximately 0.15 mg / kg to approximately 1.3 mg / kg, approximately 0.3 mg / kg to approximately 1.15 mg / kg, approximately 0.45 mg / kg to approximately 1 mg / kg, approximately 0.55 mg / kg to approximately 0.85 mg / kg, and approximately 0.65 mg / kg to approximately 0.8 mg / kg. The ranges are approximately 0.7 mg / kg to 0.75 mg / kg, 0.7 mg / kg to 2.15 mg / kg, 0.85 mg / kg to 2 mg / kg, 1 mg / kg to 1.85 mg / kg, 1.15 mg / kg to 1.7 mg / kg, 1.3 mg / kg to 1.6 mg / kg, 1.35 mg / kg to 1.5 mg / kg, 2.15 mg / kg to 3.6 mg / kg, 2.3 mg / kg to 3.4 mg / kg, 2.4 mg / kg to 3.3 mg / kg, 2.6 mg / kg to 3.15 mg / kg, 2.7 mg / kg to 3 mg / kg, 2.8 mg / kg to 3 mg / kg, or 2.85 mg / kg to 2.95 mg / kg. In some embodiments, effective doses of the BTK inhibitor or a pharmaceutically acceptable salt thereof are approximately 0.35 mg / kg, approximately 0.7 mg / kg, approximately 1 mg / kg, approximately 1.4 mg / kg, approximately 1.8 mg / kg, approximately 2.1 mg / kg, approximately 2.5 mg / kg, approximately 2.85 mg / kg, approximately 3.2 mg / kg, or approximately 3.6 mg / kg.
[0180]
[0180] In some embodiments, the BTK inhibitor or a pharmaceutically acceptable salt thereof is administered in doses ranging from 10 to 500 mg BID, including doses of 15 mg, 25 mg, 30 mg, 50 mg, 60 mg, 75 mg, 90 mg, 100 mg, 120 mg, 150 mg, 175 mg, 180 mg, 200 mg, 225 mg, 240 mg, 250 mg, 275 mg, 300 mg, 325 mg, 350 mg, 360 mg, 375 mg, and 480 mg BID.
[0181]
[0181] In some embodiments, the BTK inhibitor or a pharmaceutically acceptable salt thereof is administered in doses ranging from 10 to 500 mg QD, including doses of 15 mg, 25 mg, 30 mg, 50 mg, 60 mg, 75 mg, 90 mg, 100 mg, 120 mg, 150 mg, 175 mg, 180 mg, 200 mg, 225 mg, 240 mg, 250 mg, 275 mg, 300 mg, 325 mg, 350 mg, 360 mg, 375 mg, and 480 mg QD.
[0182]
[0182] An effective dose of a BTK inhibitor or a pharmaceutically acceptable salt thereof may be administered in single or multiple doses by any of the acceptable modes of administration for drugs of similar utility, such as buccal, sublingual, and transdermal routes, intra-arterial injection, intravenous, parenteral, intramuscular, subcutaneous, or oral.
[0183]
[0183] In certain embodiments, the route of delivery used is intraocular injection, direct injection into a given compartment of the eye, such as the vitreous humor, cornea, or retina, application of a patch to the eye, direct application of an ointment, spray, or droppable liquid to the eye, or intraocular implantation. In embodiments, the route of delivery is intravitreous injection.
[0184]
[0184] In some embodiments, the delivery routes used are local administration to the eye of a person in need, intraocular injection to the eye of a person in need, intravitreal injection to the eye of a person in need, periorbital administration to a person in need, oral administration to a person in need, intravenous injection to a person in need, or a combination thereof.
[0185]
[0185] In some embodiments, pharmaceutical compositions comprising a BTK inhibitor or a pharmaceutically acceptable salt thereof are approximately 0.001 mg / ml, approximately 0.005 mg / ml, approximately 0.01 mg / ml, approximately 0.02 mg / ml, approximately 0.03 mg / ml, approximately 0.04 mg / ml, approximately 0.05 mg / ml, approximately 0.06 mg / ml, approximately 0.07 mg / ml, approximately 0.08 mg / ml, approximately 0.09 mg / ml, approximately 0.1 mg / ml, approximately 0.2 mg / ml, approximately 0.3 mg / ml, approximately 0.4 mg / ml, approximately 0.5 mg / ml, approximately 0.6 mg / ml, approximately 0.7 mg / ml, approximately 0.8 mg / ml ml, about 0.9mg / ml, about 1mg / ml, about 1.1mg / ml, about 1.2mg / ml, about 1.3mg / ml, about 1.4mg / ml, about 1.5mg / ml, about 1.6mg / ml, about 1.7mg / ml, about 1.8mg / ml, about 1.9mg / ml, about 2.0mg / ml, about 2. 1mg / ml, about 2.2mg / ml, about 2.3mg / ml, about 2.4mg / ml, about 2.5mg / ml, about 2.6mg / ml, about 2.7mg / ml, about 2.8mg / ml, about 2.9mg / ml, about 3.0mg / ml, about 3.1mg / ml, about 3.2mg / ml, about 3.3mg / ml ml, about 3.4mg / ml, about 3.5mg / ml, about 3.6mg / ml, about 3.7mg / ml, about 3.8mg / ml, about 3.9mg / ml, about 4.0mg / ml, about 4.1mg / ml, about 4.2mg / ml, about 4.3mg / ml, about 4.4mg / ml, about 4.5mg / ml, about 4.6mg / ml, about 4.7mg / ml, about 4.8mg / ml, about 4.9mg / ml, about 5.0mg / ml, about 5.1mg / ml, about 5.2mg / ml, about 5.3mg / ml, about 5.4mg / ml, about 5.5mg / ml, about 5.6mg / ml, about 5.7mg / ml, about 5.8m g / ml, approximately 5.9 mg / ml, approximately 6.0 mg / ml, approximately 6.1 mg / ml, approximately 6.2 mg / ml, approximately 6.3 mg / ml, approximately 6.4 mg / ml, approximately 6.5 mg / ml, approximately 6.6 mg / ml, approximately 6.7 mg / ml, approximately 6.8 mg / ml, approximately 6.9 mg / ml, approximately 7.0 mg / ml , about 7.1mg / ml, about 7.2mg / ml, about 7.3mg / ml, about 7.4mg / ml, about 7.5mg / ml, about 7.6mg / ml, about 7.7mg / ml, about 7.8mg / ml, about 7.9mg / ml, about 8.0mg / ml, about 8.1mg / ml, about 8.2mg / ml, about 8.3mg / ml, about 8.4mg / ml, about 8.5mg / ml, about 8.6mg / ml, about 8.7mg / ml, about 8.8mg / ml, about 8.9mg / ml, about 9mg / ml, Approx. 9.1mg / ml, approx. 9.2mg / ml, approx. 9.3mg / ml, approx. 9.4mg / ml, approx. 9.5mg / ml, approx. 9.6mg / ml, approx. 9.7mg / ml, approx. 9.8mg / ml, about 9.9mg / ml, about 10mg / ml, about 10.5mg / ml, about 11mg / ml, about 11.5mg / ml, about 12mg / ml, about 12.5mg / ml, about 1 3mg / ml, about 13.5mg / ml, about 14mg / ml, about 14.5mg / ml, about 15mg / ml, about 16mg / ml, about 17mg / ml, about 18mg / ml, about 1 The drug is administered by injection in doses of 9 mg / ml, approximately 20 mg / ml, approximately 21 mg / ml, approximately 22 mg / ml, approximately 23 mg / ml, approximately 24 mg / ml, approximately 25 mg / ml, approximately 26 mg / ml, approximately 27 mg / ml, approximately 28 mg / ml, approximately 29 mg / ml, approximately 30 mg / ml, approximately 31 mg / ml, approximately 32 mg / ml, approximately 33 mg / ml, approximately 34 mg / ml, approximately 35 mg / ml, approximately 36 mg / ml, approximately 37 mg / ml, approximately 38 mg / ml, approximately 39 mg / ml, approximately 40 mg / ml, approximately 41 mg / ml, approximately 42 mg / ml, approximately 43 mg / ml, approximately 44 mg / ml, approximately 45 mg / ml, approximately 46 mg / ml, approximately 47 mg / ml, approximately 48 mg / ml, approximately 49 mg / ml, or approximately 50 mg / ml.
[0186]
[0186] In some embodiments, the pharmaceutical composition comprising a BTK inhibitor or a pharmaceutically acceptable salt thereof is in approximately 0.01 ml, approximately 0.02 ml, approximately 0.03 ml, approximately 0.04 ml, approximately 0.05 ml, approximately 0.06 ml, approximately 0.07 ml, approximately 0.08 ml, approximately 0.09 ml, approximately 0.1 ml, approximately 0.15 ml, approximately 0.2 ml, approximately 0.25 ml, approximately 0.30 ml, approximately 0.35 ml, approximately 0.40 ml, approximately 0.45 ml, approximately 0.5 ml, approximately 0.55 ml, approximately 0.60 ml, approximately 0.65 ml, approximately 0.70 ml, approximately 0.75 ml, approximately 0.80 ml, approximately 0.85 ml, approximately 0.90 ml, approximately 0.95 ml, and approximately 1.0 ml. It is administered by injection in volumes of approximately 1.1 ml, 1.2 ml, 1.3 ml, 1.4 ml, 1.5 ml, 1.6 ml, 1.7 ml, 1.8 ml, 1.9 ml, 2.0 ml, 2.5 ml, 3.0 ml, 3.5 ml, 4.0 ml, 4.5 ml, 5.0 ml, 5.5 ml, 6.0 ml, 6.5 ml, 7.0 ml, 7.5 ml, 8.0 ml, 8.5 ml, 9.0 ml, 9.5 ml, 10.0 ml, 15.0 ml, 20.0 ml, 25.0 ml, 30.0 ml, 35.0 ml, 40.0 ml, 45.0 ml, or 50.0 ml.
[0187]
[0187] In some embodiments, a pharmaceutical composition comprising a BTK inhibitor or a pharmaceutically acceptable salt thereof is administered by intravitreal or intraocular injection in volumes of approximately 0.001 ml, approximately 0.005 ml, approximately 0.010 ml, approximately 0.015 ml, approximately 0.020 ml, approximately 0.025 ml, approximately 0.030 ml, approximately 0.035 ml, approximately 0.040 ml, approximately 0.045 ml, approximately 0.05 ml, approximately 0.055 ml, approximately 0.06 ml, approximately 0.065 ml, approximately 0.07 ml, approximately 0.075 ml, approximately 0.08 ml, approximately 0.085 ml, approximately 0.09 ml, approximately 0.095 ml, or approximately 0.1 ml.
[0188]
[0188] In some embodiments, the BTK inhibitor or a pharmaceutically acceptable salt thereof is administered to the subject intermittently, known as intermittent administration. “Intermittent administration” means that there is a period of discontinuation after an effective dose of the BTK inhibitor or a pharmaceutically acceptable salt thereof, followed by another period of administration, etc. In each administration period, the frequency of administration can be independently selected from three times a day, twice a day, daily, once a week, twice a week, three times a week, four times a week, five times a week, or six times a week in the case of topical administration to the eye, or it can be monthly in the case of intravitreal or intraocular injection to the eye.
[0189]
[0189] "Discontinuation period," "discontinuation period," or "break period" refers to the period during which administration of a BTK inhibitor or a pharmaceutically acceptable salt thereof is discontinued. The discontinuation period may be longer, shorter, or the same as the administration period. During the discontinuation period, other therapeutic agents other than BTK inhibitors or pharmaceutically acceptable salts thereof may be administered.
[0190]
[0190] In the embodiment, a pharmaceutical composition comprising a BTK inhibitor or a pharmaceutically acceptable salt thereof is administered to a human subject in need by intravitreal or intraocular injection for a first administration period to treat an ophthalmic disease, followed by a discontinuation period, followed by a second administration period, and so on, where the ophthalmic disease includes inflammation of the eye, dry eye disease (including tear-deficient dry eye disease, evaporative dry eye disease, and mixed dry eye disease of tear-deficient and evaporative types), uveitis (including infectious uveitis, non-infectious uveitis, anterior uveitis, intermediate uveitis, posterior uveitis, and panuveitis), postoperative inflammation of the eye, corneal transplantation, ocular graft-versus-host disease (GVHD), allergy, allergic conjunctivitis, non-allergic conjunctivitis, and infectious conjunctivitis.
[0191]
[0191] In the embodiment, a pharmaceutical composition comprising a BTK inhibitor or a pharmaceutically acceptable salt thereof is administered topically to a human subject in need for a first administration period to treat an ophthalmic disease, followed by a discontinuation period, followed by a second administration period, and so on, wherein the ophthalmic disease includes inflammation of the eye, dry eye diseases (including tear-deficient dry eye diseases, evaporative dry eye diseases, and mixed dry eye diseases of tear-deficient and evaporative types), uveitis (including infectious uveitis, non-infectious uveitis, anterior uveitis, intermediate uveitis, posterior uveitis, and panuveitis), postoperative inflammation of the eye, corneal transplantation, ocular graft-versus-host disease (GVHD), allergies, allergic conjunctivitis, non-allergic conjunctivitis, and infectious conjunctivitis.
[0192]
[0192] In the case of topical administration to the eye, the first administration period, the second administration period, and the discontinuation period are independently selected from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 1 month, 5 weeks, 6 weeks, 7 weeks, 2 months, 9 weeks, 10 weeks, 11 weeks, 3 months, 13 weeks, 14 weeks, 15 weeks, 4 months, and more than that number of days, and the pharmaceutical composition containing a BTK inhibitor or a pharmaceutically acceptable salt thereof is administered to the subject 3 times a day, 2 times a day, daily, once a week, twice a week, 3 times a week, 4 times a week, 5 times a week, 6 times a week, or monthly. In the embodiment, the first administration period is the same length as the second administration period. In the embodiments, the first administration period is shorter than the second administration period. In the embodiments, the first administration period is longer than the second administration period. In the embodiments, the first and second administration periods are approximately one week, with the BTK inhibitor or a pharmaceutically acceptable salt thereof administered to the subject daily, and the discontinuation period is approximately two weeks. In the embodiments, the first and second administration periods are approximately three weeks, with the BTK inhibitor or a pharmaceutically acceptable salt thereof administered to the subject daily, and the discontinuation period is approximately two weeks. In the embodiments, the first and second administration periods are approximately three weeks, with the BTK inhibitor or a pharmaceutically acceptable salt thereof administered to the subject weekly, and the discontinuation period is approximately two weeks. In the embodiments, the first and second administration periods are approximately four weeks, with the BTK inhibitor or a pharmaceutically acceptable salt thereof administered to the subject daily, and the discontinuation period is approximately two weeks. In this embodiment, the first and second administration periods are approximately 4 weeks, during which a BTK inhibitor or a pharmaceutically acceptable salt thereof is administered to the subject weekly, with a discontinuation period of approximately 2 weeks.
[0193]
[0193] In the case of intravitreous or intraocular injection into the eye, the first administration period, the second administration period, and the discontinuation period are independently selected from the group consisting of 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, and 1 year, and the pharmaceutical composition containing the BTK inhibitor or a pharmaceutically acceptable salt thereof is administered to the subject monthly, every other month, once every 3 months, once every 4 months, once every 5 months, once every 6 months, or once a year. In the embodiment, the first administration period is the same length as the second administration period. In the embodiment, the first administration period is shorter than the second administration period. In the embodiment, the first administration period is longer than the second administration period.
Claims
1. A pharmaceutical composition for treating an ophthalmic disease in a human subject, comprising an effective amount of a Bruton's tyrosine kinase (BTK) inhibitor compound.
2. The pharmaceutical composition of claim 1, wherein the BTK inhibitor compound is 1-(4-(((6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl)amino)methyl)-4-fluoropiperidin-1-yl)prop-2-en-1-one or a pharma- ceutically acceptable salt thereof.
3. A pharmaceutical composition as described in claim 1 for reducing ocular inflammation in a human subject.
4. The pharmaceutical composition described in any one of claims 1 to 3, wherein the ophthalmic disease is eye inflammation.
5. The pharmaceutical composition described in any one of claims 1 to 3, wherein the ophthalmic disease is selected from dry eye disease, uveitis, postoperative eye inflammation, corneal transplantation, ocular graft-versus-host disease (GVHD), allergy, allergic conjunctivitis, non-allergic conjunctivitis, or infectious conjunctivitis.
6. The pharmaceutical composition described in any one of claims 1 to 3, wherein the ophthalmic disease is aqueous tear-deficient dry eye disease, evaporative dry eye disease, or mixed aqueous tear-deficient and evaporative dry eye disease.
7. The pharmaceutical composition described in any one of claims 1 to 3, wherein the ophthalmic disease is infectious uveitis, non-infectious uveitis, anterior uveitis, intermediate uveitis, posterior uveitis, or panuveitis.
8. A pharmaceutical composition according to any one of claims 1 to 7, for local administration to the eye of a human subject, for intraocular injection into the eye of a human subject, for intravitreal injection into the eye of a human subject, for periocular administration to a human subject, for oral administration to a human subject, or for intravenous injection into a human subject.
9. The pharmaceutical composition of claim 1, comprising nanoparticles comprising the BTK inhibitor compound.
10. The pharmaceutical composition of any one of claims 1 to 9, which is in a dosage form selected from a solution, a suspension, an emulsion, a microemulsion, an ointment, a gel, a hydrogel, a drug delivery device, a tablet, or a capsule.
11. The pharmaceutical composition of claim 10, wherein the drug delivery device is an intraocular insert for sustained release of the BTK inhibitor compound.
12. The pharmaceutical composition of claim 10, wherein the dosage form is a sustained release form, an extended release form, a controlled release form, or a combination thereof.
13. The pharmaceutical composition of claim 12, wherein the sustained release, extended release, or controlled release dosage form comprises a pegylated BTK inhibitor.
14. The pharmaceutical composition of any one of claims 1 to 13, comprising particles comprising the BTK inhibitor compound, the particles self-aggregating into a depot upon administration.
15. The particle further comprises a polymer.
15. The pharmaceutical composition of claim 14.
16. The pharmaceutical composition of claim 15, wherein the polymer is selected from the group consisting of chitosan, gelatin, sodium alginate, albumin, poly-L-lactide (PLLA), poly(lactic acid) (PLA), poly(glycolic acid) (PGA), polylactic-glycolic acid copolymer (PLGA), polycaprolactone, polylactic-caprolactone copolymer, poly(methyl methacrylates), poloxamer, poly(ethylene glycol) (PEG), PEG-PLLA, PEG-PLGA, poly(methyl vinyl ether / maleic anhydride), cellulose acetate phthalate, and combinations thereof.
17. The pharmaceutical composition according to any one of claims 1 to 16, for reducing overexpression of lymphocyte function associated antigen (LFA-1) in T cells of the eye of a human subject.
18. A pharmaceutical composition according to any one of claims 1 to 17 for inhibiting intercellular adhesion molecule 1 (ICAM-1) in the eye of a human subject.
19. The pharmaceutical composition described in claim 18, wherein the ICAM-1 is present on antigen presenting cells (APCs) in the eye of a human subject, present on vascular endothelial cells in the eye of a human subject, or present on corneal epithelial cells in the eye of a human subject.
20. A pharmaceutical composition described in any one of claims 1 to 19 for reducing the level of inflammatory cytokines in a human subject.
21. The pharmaceutical composition of claim 20, wherein the inflammatory cytokine is selected from IL-1β, IL-6, INF-γ, TNF-α, or a combination thereof.
22. A pharmaceutical composition described in any one of claims 1 to 21, for reducing ocular surface antigen presenting cells (APCs), APC maturation, or both.
23. The pharmaceutical composition described in claim 22, wherein the APC is a monocyte, a macrophage, a dendritic cell, a B cell, or a combination thereof.
24. The human subject having a marker for an ophthalmic disease, 24. The pharmaceutical composition of any one of claims 1 to 23, wherein the marker is elevated inflammatory cytokines, elevated chemokines, elevated matrix metalloproteinases (MMPs), elevated toll-like receptor 2 (TLR2), elevated nuclear factor kappa B (NF-κB), elevated tumor necrosis factor alpha (TNF-α), or a combination thereof.
25. The pharmaceutical composition of claim 24, wherein the inflammatory cytokine is selected from IL-1β, IL-6, INF-γ, TNF-α, or a combination thereof.
26. The pharmaceutical composition of any one of claims 1 to 25, wherein the human subject has an autoimmune disease or an inflammatory disease in addition to an ophthalmic disease.
27. The pharmaceutical composition according to claim 26, wherein the autoimmune disease or inflammatory disease is rheumatoid arthritis, Sjogren's syndrome, Vogt-Koyanagi-Harada (VKH) disease, juvenile idiopathic arthritis, Behcet's disease, systemic sarcoidosis, spondyloarthropathy (such as HLA-B27-associated spondyloarthropathy), Blau syndrome, or IgG-4-related disease (IgG4-RD).
28. The pharmaceutical composition of any one of claims 1 to 27, which is used to be administered three times a day, twice a day, once a day, every other day, three times a week, twice a week, every week, every two weeks, twice a month, every month, every two months, or every three months.
29. A pharmaceutical composition for reducing an immune response in a human subject having an ophthalmic disease, comprising an effective amount of a Bruton's tyrosine kinase (BTK) inhibitor compound.
30. The pharmaceutical composition of claim 29, wherein the immune response is an innate immune response, an adaptive immune response, or both.
